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ABSTRACT
Measles virus (MV)-infected persons have been found to be at a greatly increased risk of 
developing respiratory infections caused mainly by Staphylococcus aureus and Mycobacterium 
tuberculosis. Secondary microbial infections have been implicated as important causes of 
morbidity and mortality in patients with measles. Polymorphonuclear leukocytes (PMNL), the 
first cells of the immune system to migrate to the site o f microbial invasion, are the principal 
cells involved in the immune response to invasion of the host by microbes, particularly bacteria 
and fungi.
Tliis study set out to determine whether MV has any directs effects on PMNL functions, that 
could account for the increased susceptibility of MV-infected persons to secondary microbial 
infections. Therefore, the specific objectives of this study were :
(a) to determine which, if any, PMNL functions (i.e. chemotaxis, degranulation, phagocytosis, 
oxidative burst), are altered by exposure to MV in vitro.
(b) to determine whether MV can, directly or indirectly, induce apoptosis in vitro.
(c) to determine whether virus attenuation or heat inactivation of MV strains have any effect 
on these functions.
(d) to determine whether ligation of the MV-specific receptor, CD46, by CD46 antibody can alter 
any of the PMNL functions mentioned above, or induce apoptosis.
PMNL isolated from 5 to 7 healthy individuals using Ficoll Histopaque®-1077, purified by lysing 
contaminated red blood cells with ammonium chloride and washed with PBS, were exposed to 
three MV strains Schwartz (vaccine), Jhb 25 (vaccine-like) and D1317 (wild-type), and their 
heat-inactivated forms (inactivated by heating at 56° C for 1 hour). Each of these strains represent 
different degrees of MV attenuation : vaccine > vaccine-like > wild type, and all assays used 
similar virus inputs. PMNL assays and an apoptosis assay were conducted on the above- 
mentioned samples.
A specific antibody to CD46, was used to ligate CD46 receptors on PMNL, and its ability to 
affect interleukin-8 (IL-S)-induced chemotaxis, and to induce apoptosis was determined. An
IV
isotope control antibody, IgG! was used in addition to the CD46 antibody. These assays were 
conducted to determine if by ligating the CD46 receptor used for entry by MV, similar effects 
on PMNL could be noted to those of the MV strains.
Chemotaxis was significantly reduced by exposure to all MV strains, the greatest reduction being 
seen in the wild-type D1317-exposed PMNL. A slight recovery of function was observed when 
PMNL were exposed to heat-inactivated forms of these strains. However, this recovery was not 
significant, as chemotactic indices obtained remained significantly decreased relative to the 
uninfected control.
A reduction in phagocytic ability was observed in PMNL exposed to the three MV strains. Both 
the proportions of cells phagocytosing bacteria (E. coli), and the number of bacteria within the 
cells (measured as fluorescence intensity), were reduced relative to the uninfected control. The 
reduction was more pronounced in the wild-type D 1317-exposed PMNL. Heat inactivation of 
viral strains brought about some improvement, but failed to restore the PMNL function. It was 
clear that the ability of PMNL to engulf bacteria was compromised by exposure of these cells to 
the different MV strains.
The trend observed in phagocytosis, was also observed with the oxidative burst function. Both 
the percentage of cells producing reactive oxygen intermediates, and their mean fluorescence 
intensity were decreased in PMNL exposed to all three MV strains. Heat inactivation had little 
impact on the percentage of cells releasing reactive oxygen intermediates.
With degranulation, MV-exposed PMNL showed no changes in the percentages of enzyme ((3- 
glucuronidase) released relative to the uninfected control, in either the absence or presence of IL- 
8. Inter-strain comparisons also did not show significant differences in the percentages of enzyme 
released. Furthermore, heat inactivation of all strains had no impact on degranulation of PMNL.
All three MV strains used induced apoptosis of PMNL, the greatest reduction occurring in those 
exposed to wild-type D1317 MV strain. This strain caused a 907c increase in apoptosis when 
compared to the uninfected control. Heat inactivation only significantly decreased apoptosis
induced by the wild type MV strain. Even though apoptosis was decreased to some extent by heat 
inactivation o f the MV strains relative to their untreated forms, it was still significantly high 
when compared to the uninfected control.
Reductions in chemotactic indices were also observed in PMNL exposed to two CD46 antibody 
concentrations (5 ug/ml and 25 ug/ml), with the greatest reduction observed in PMNL exposed 
to the higher concentration of the CD46 antibody. Interestingly, exposure to the two 
concentrations of the isotype control antibody IgGj (5 ug/ml and 25 ug/ml) was accompanied by 
an increase in the chemotactic index, suggesting that ligation of Fc receptors, which bind lgG, 
molecules, may be involved in enhancing chemotaxis. Ligation of the MV cellular receptor, 
CD46 with a specific antibody, also induced apoptosis. Apoptosis in the isotype control IgG,- 
exposed PMNL, although raised relative to the uninfected control, was less than that observed 
in the CD46-exposed PMNL. Increasing the concentration of IgG! antibody led to a reduction 
in apoptosis. This observation, like the one noted above in chemotaxis, suggests a protective 
effect here imparted by higher concentrations of the iso type control antibody, IgG,. Therefore the 
mechanism(s) involved in the suppression of IL-8 induced chemotaxis and in the induction of 
apoptosis appears to involve the binding of MV to its cellular receptor on PMNL. This is further 
supported by the fact that (i) MV does not replicate in PMNL and (ii) exposure of MV to PMNL 
in all experiments was only for one hour.
In summary, the results indicate that MV has the ability to directly incapacitate a number of 
PMNL functions (chemotaxis, phagocytosis and oxidative burst), and to induce apoptosis. This 
most likely occurs at the stage of vims attachment. It is therefore likely that MV, by binding to 
PMNL in vivo, (in particular, the wild-type strain of MV) may play an important role in 
compromising innate cellular immunity in the MV-infected host, and in so doing predisposes 
the individual to secondary microbial infections.
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CHAPTER 1
INTRODUCTION
MEASLES VIRUS
Measles virus (MV), the cause of measles, is the most contagious human agent, resulting in 
frequent acute admissions to paediatric wards in many countries, particularly in third world 
countries (Nur et al., 1999). The virus belongs to the genus Morbillivirus, within the 
Paramyxoviridae family of RNA viruses (Orvell, 1994). Despite the availability of a vaccine and 
the establishment of the global measles vaccination program by the World Health Organization 
(WHO), approximately one million children die annually from measles, the majority of whom 
are from underdeveloped countries, where large communities remain unvaccinated and 
malnourished (Gellin and Katz, 1994a).
In these countries, it is estimated that between three and fifteen percent of children contracting 
measles die from this disease. In fact, it has been shown that measles and its complications 
account for more deaths of children worldwide, than do all other childhood vaccine-preventable 
diseases combined, or than any other single infectious agent (Gellin and Katz, 1994a).
1.1 Classification
Measles virus is a member of the family Paramyxoviridae and shows structural and biochemical 
features associated with these viruses. It lacks the virion-associated enzyme Neuraminidase and 
has therefore been grouped into a separate genus, the Morbillivirus. Measles is the type species 
of this group whose other members include : peste des petits ruminants which infects sheep and 
goats; rinderpest which infects cattle, canine distemper virus (CDV) which infects dogs, and 
phocine distemper virus (PDV) which infects seals and sea-lions. All these viruses exhibit 
antigenic similarities, and all produce similar diseases in their host species. Both MV and CDV 
can persist in the central nervous system (CNS) and produce chronic neurological diseases. It is 
not known whether the other members of the group can do likewise (Carter and ter Meulen, 
1995).
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1.2 Morphology
Measles vims, like all other members of the Paramyxoviridae family, is an enveloped virus 
(Collier and Oxford, 1993). The virion is bounded by a lipid bilayer envelope, derived from the 
host cell. Embedded in this envelope are virion glycoproteins (Carter and ter Meulen, 1995). 
When viewed under an electron microscope, measles virions appear roughly spherical, but 
pleomorphic and have diameters ranging from 100 to 300 nm (Lund et al., 1984; Griffin and 
Bellini, 1996). Also embedded in the lipid bilayer through their hydrophobic tails and protruding 
through as surface projections (peplomers) with a length of 9 to 15 nm, are the viral 
transmembrane haemagglutinin (H) and fusion (F) glycoproteins (Gerald, et al. 1986; Carter and 
ter Meulen, 1995; Griffm and Bellini, 1996; Oxman, 1997). When examined by electron 
microscopy, the H proteins peplomers appear conical in shape, while the F proteins peplomers 
are said to be dumbbell-shaped with ends o f unequal sizes (Norrby and Oxman, 1990). Both 
proteins are estimated to be 15-16 nm length, excluding the transmembrane portions, which are 
estimated to be an additional 7-8 nm (Bellini et a l, 1994). The matrix protein (M) lies on the 
inside of the envelope, and is thought to interact with both the H and F glycoproteins, and with 
the nucleocapsid to play a role in virion maturation. The primary nucleocapsid (N) protein 
encases the virion RNA ( Lund et al., 1984; Carter and ter Meulen, 1995; Griffin and Bellini, 
1996). The nucleocapsid has a helical structure with a diameter of of 21 nm, a central hole of 5 
nm and a pitch of 6 nm. Bound to genomic RNA, are the phospho (P) and large (L) proteins. The 
total length of free intact nucleocapsid is packed within the envelope in the form of a 
symmetrical coil.
Virions may also contain actin from the cellular cytoskeleton (Tyrrell and Norrby, 1978; 
Fragraeus et a l, 1983), which is involved in the final steps of budding from the plasma 
membrane (Stallcup et al., 1983; Bohn et al., 1986). See Figure 1.1.
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Fig. 1.1 : Schematic diagram o f Measles virus. Adapted from Oxman, 1997. 
1.3 Genome
The genome o f MV is made up o f a single-stranded, non-segmented RNA o f negative polarity. 
The length o f this genome is approximately 16 000 ribonucleotides and its molecular mass 
approaches 4,5 x 106 daltons (Baczko et a l,  1983; Lund e ta l,  1984). It makes up approximately 
5% o f the nucleocapsid weight (Waters et aL, 1972). The entire genome o f the Edmonston strain 
of measles virus has been sequenced (Bellini etaL, 1985; Bellini and Eng hind, 1985; Rozenblatt 
et al., 1985; Alkhatib and Briedis, 1986; Bhnnberg et aL, 1988). The genome starts from the 3' 
end with a leader sequence o f 55 nucleotides. This sequence shows a high degree of 
complementarity to 40 nucleotides at the 5’ end o f the genome, suggesting the possibility for 
formation o f a panhandle structure (Crowley et a l,  1988).
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The genome encodes six major structural proteins from the six genes and an additional two 
nonstructural proteins from the P gene. The gene order is as follows : 3' N, P (plus C and V), M, 
H and L (large polymerase protein) 5' (Richardson etal., 1985; Dowling e ta l,  1986) withCUU 
as the intergenic trinucleotide (Crowley et a l, 1988; Carter and ter Meulen, 1995). The mRNAs 
for the MV structural genes are functionally monocystronic with one exception. Within the P 
gene a second open reading frame is found, encoding for the non-structural protein C. As a third 
protein, V protein is expressed from the same gene containing the amino-terminal half of P, but 
with a different, cysteine-rich carboxyl terminal domain (Carter and ter Meulen, 1995).
1.4 The Proteins
The characteristics of the measles virus proteins are summarised in Table 1.1.
1.4.1 Nucleocapsid (N) protein
The N protein is the most abundant of all viral glycoproteins. Its mRNA is the first to be 
transcribed from the genome. Synthesis of this protein takes place on free ribosomes, folded in 
the cytoplasm (Gombart et a l, 1993), and phosphorylated on serine and threonine residues 
(Robbins and Bussel, 1979). On polyacrylamide gels, the N protein normally appears as a 60 000 
daltons band, but is often cleaved by cellular proteases during extraction to 45 000 and 41 000 
daltons products (Graves, 1981). The N protein surrounds viral genomic and messenger RNAs 
possessing the leader sequence (Castaneda and Wong, 1990) to form the nucleocapsid structures 
(Udemand Cook, 1984). By so doing, it condenses the RNA into a smaller, more stable and more 
readily packaged form, and hence confers the helical form on the nucleocapsid giving it a 
‘herringbone’ appearance when viewed under an electron microscope (Carter and ter Meulen, 
1995). The function of the N protein is to protect the viral RNA (Orvell, 1994). The nucleocapsid 
structure is the required template for both replication and transcription, and, in conjunction with 
the P and L proteins, comprises the ribonucleoprotein complex (Ray and Fujinami, 1987). N can 
be transported to the nucleus but is usually retained in the cytoplasm by binding to P (Huber et 
a l, 1991). Amino acid sequence conservation is strong in the N-terminal portion of the protein, 
which contains the P binding site (Gombart et a l, 1993).
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TABLE 1.1 : Characteristics of the measles virus proteins
P r o te in A p p a r e n t  s iz e L o c a t i o n S u g g e s t e d  f u n c t i o n / s p e c i a l  f e a tu r e s
A m i n o  a c id  
r e s id u e s
kd I n f e c te d  ce ll V i r io n
N u c l e o p r o t e i n  ( N ) 5 2 5 6 0 C y t o p l a s m ;  n u c l e u s  
( p e r s i s t e n t  i n f e c t i o n s )
N u c l e o c a p s i d M o s t  a b u n d a n t  o f  v i r a l  p r o t e i n s ;  c lo s e ly  
a s s o c i a t e d  w i t h  f u l l - l e n g t h  - a n d  +  s e n s e  R N A  
to  f o r m  n u c l e o c a p s i d s ;  p h o s p h o r y l a t e d
P h o s p h o p r o t e i n  ( P ) 5.07 7 2 C y t o p l a s m N u c l e o c a p s i d M o r e  a b u n d a n t  in  i n f e c t e d  c e l l s  t h a n  in  
v i r i o n s ;  l ik e ly  i n v o l v e m e n t  in  r e g u l a t i o n  o f  
t r a n s c r i p t i o n  a n d  r e p l i c a t i o n ;  c o m p l e x  
f o r m a t io n  w i th  N  a n d  L ; p h o s p h o r y l a t e d
C 186 21 C y t o p l a s m  a n d  
n u c l e u s
N o t  p r e s e n t R e a d  f r o m  th e  s a m e  t r a n s c r i p t  as  P, b u t  in 
d i f f e r e n t  r e a d i n g  f r a m e s ;  d o w n r e g u l a t e s  
t r a n s c r i p t i o n  ?
V 2 9 8 4 0 C y t o p l a s m N o t  p r e s e n t R e a d  f r o m  a n  “ e d i t e d ” t r a n s c r i p t  o f  P  g e n e ;  
p h o s p h o r y l a t e d ;  c y s t e i n e - r i c h  C O O H  
t e r m i n u s ;  f u n c t i o n  u n k n o w n
M a t r ix  o r  m e m b r a n e  
(M )
3 3 5 38 I n n e r  lea f le t  i d ' p l a s m a  
m e m b r a n e  c y t o p l a s m  
( p e r s i s t e n t  i n f e c t i o n s )
I n n e r  s u r f a c e  o f  
m e m b r a n e
V i r i o n  a s s e m b l y  a n d  b u d d i n g ;  i n h i b i t s  
t r a n s c r i p t i o n  ?
F u s i o n  (F ) 5 5 3 6 0 H R ,  G o lg i ,  an d  p l a s m a  
m e m b r a n e
T r a n s m e m b r a n e  ( t y p e  
1) s u r f a c e  c o n j u n c t i o n  
w i t h  p r o t e in
G l y c o s y l a t e d  m e m b r a n e  f u s i o n ,  v i ru s  e n t r y  
a n d  h a e m o l y s i s  a c t i v i t y  in  H ; 1 8 - k d  a c t iv e  
f o r m  is  c l e a v e d : F 0 ( 6 0  k d ) - 2  s u b u n i t s  F , (41 
k d )  a n d  F 2
H e m a g g l u t i n i n  ( H ) 6 1 7 78 E R ,  G o lg i ,  a n d  p l a s m a  
m e m b r a n e
T r a n s m e m b r a n e  ( t y p e  
I I )  s u r f a c e  p r o te in
R e c e p t o r  b in d in g ;  h e m a g g l u t i n a t i o n  a c t iv i ty ;  
d i s u l f i d e  l i n k e d  d i m e r ;  g l y c o s y l a t e d
L a r g e  (L ) 2 ,2 1 3 2 0 0 C y t o p l a s m N u c l e o c a p s i d C a t a l y t i c  c o m p o n e n t  o f  v i r a l  p o ly m e r a s e ;  
l e a s t  a b u n d a n t  p r o t e in ;  R N A  t r a n s c r ip t io n  a n d  
r e p l i c a t i o n ;  c o m p l e x  f o r m e d  w i t h  P
Adapted from Griffin and llellini, 1996
1.4.2 P. C and V proteins
The P protein is one of the three proteins encoded for by the P gene. The other two are the C and 
V proteins. Only small amounts of the P protein are present in the packaged virion despite the 
fact that this protein is the most abundant in the infected cell, the reason being its sensitivity to 
proteolysis. This protein is 72 Kda in size. Although the P and C proteins are translated using 
different initiator methionine codons and overlapping reading frames, they are encoded from the 
same messenger RNA (Bellini, et al., 1985). The V protein on the other hand shares the initiator 
methionine and the amino terminal 231 amino acid residues of the P protein (Griffin and Bellini, 
1996). The P protein forms part of the replicase complex (Robbins and Bussel, 1979; Stallcup 
et al., 1979; Huber et al., 1991). The function of the other two proteins is not clear, although 
there has been speculation that they are probably involved in regulation of transcription and/or 
replication (Griffin and Bellini, 1996).
1.4.3 M atrix (M) protein
The M protein is strongly associated with the inner layer of the plasma membrane and the 
nucleocapsid in infected cells (Hirano et al., 1992). This protein together with the H and F 
glycoproteins make up the viral envelope (Griffin and Bellini, 1996). M appears to interact with 
the intracytoplasmic regions of one or both transmembrane glycoproteins (H and F), and the 
speculation is that by so doing, it stabilizes or organizes the membrane environment in 
preparation for budding of virions (Tyne 11 and Ehmst, 1979). It also inhibits transcription when 
bound to the viral ribonucleoprotein (Suryanarayana et al., 1994).
1.4.4 Fusion (F) protein
The F protein and the H protein make up the spikes observed under the electron microscope 
(Carter and ter Meulen, 1995). Comparedto theH protein, the F protein has a reverse orientation. 
It is anchored in the viral membrane with a hydrophobic stretch of 29 amino acids located close 
to the C tenninus of the molecule (Orvell, 1994). It is synthesised as an inactive protein and 
needs to be cleaved into two disulfide-linked proteins, a non-glycosylated FI protein (amino acid
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residues 113-550 from the N terminus) with a molecular weight of 41 000 daltons and a 
glycosylated (three potential glycosylation sites, viz. residues 29, 61 and 67) F2 protein with a 
molecular weight of about 18 000-20 000 daltons, in order to become biologically active (i.e. 
exact fusion or haemolytic activity). The N terminus o f the FI protein is formed by a second 
hydrophobic stretch of 25 amino acids from amino acid residues 113 to 137 with sequence 
homology to other paramyxoviruses. This hydrophobic terminus is reorientated by cleavage of 
the F protein, and thus becoming active in membrane fusion. A third hydrophobic domain of 29 
amino acids is located in the N terminus of the precursor F protein. This part of the molecule is 
called the signal peptide and it is used for transportation of F through the rough endoplasmic 
reticulum It is cleaved off from the mature F protein. The F protein gives rise to haemolysis 
inhibiting (HLI) antibodies when injected into laboratory animals. These antibodies can protect 
against disease caused by measles virus, but, in in vitro tests, absent or only low titres of 
neutralizing antibodies are found in such sera (Orvell, 1994). The F protein plays a role in virus 
penetration into the host cell and promotes fusion of MV-infected cell membranes (Morgan and 
Rapp, 1977;Choppin etal., 1981).
1.4.5 Haemagglutinin (H) protein
The H protein is the receptor binding and haemagglutinating (Varsanyi et al., 1984) protein. It 
is a type 11 transmembrane glycoprotein that resides on the surfaces of infected cells and virions 
as a disulfide-linked homodimer (Alkhatib and Briedis, 1986; Schneider-Schaulies et a l, 1990). 
Viewed under the electron microscope, isolated peplomers appear conical in shape (Norrby and 
Oxman, 1990). This protein which is made up o f 617 amino acids, is anchored in the viral 
membrane by a hydrophobic region, 24 amino acids in length, located close to the N terminus 
of the molecule. The protein has five potential N-linked glycosylation sites closely located 
between amino acids residues 168-240 in the N-terminal part of the molecule (Orvell, 1994). The 
H protein is closely associated with the F protein on the cell surface (Malvoisin and Wild, 1993) 
and acts in conjunction with F protein during fusion and entry ( Wild et al., 1991; Cattaneo and 
Rose, 1993). It is folded and dimerized in the endoplasmic reticulum (ER) (Bellini et al., 1983; 
Malvoisin and Wild, 1993), and has 13 strongly conserved cysteines, all in the ectodomain 
(Griffin and Bellini, 1996). It induces the production of neutralizing antibodies when injected
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into laboratory animals. The epitopes giving rise to neutralizing and protective antibodies have 
not yet been fully defined (Orvell, 1994).
1.4.6 Large (L) protein
This protein is present in small quantities in the infected cell and is associated with the viral 
nucleocapsid in the cell and in the virion (Stallcup et a l, 1979). It has been found to be highly 
homologous to the polymerases of other negative strand viruses. It contains a duplicated Gly- 
Asp-Asp-Asp motif flanked with hydrophobic amino acids common to RNA polymerases 
(Blumberg et al., 1988).
1.5 Cellular receptor
The membrane cofactor CD46 has been identified as the cellular receptor for MV. This cellular 
receptor is present on human and monkey cells which interact with the H protein, and is a 
glycoprotein (Norrby, 1962; Krah, 1989). It is the only glycoprotein that has demonstrated its 
ability to confer MV binding and replication to previously non-susceptible murine cells (Dorig 
e ta l, 1993; Naniche etal., 1993). This receptor was identified by the generation of a monoclonal 
antibody that blocked infection of HeLa cells (Naniche etal., 1992), and was subsequently shown 
to recognize CD46 (Naniche et al., 1993). This receptor is distributed throughout human tissue 
and has complement regulatory function. It normally binds complement components C3b and 
C4b and acts as a cofactor in the proteolytic activation of C3b/C4b by factor I (Liszewski and 
Atkinson, 1992). MV infection of cells or expression of the H protein alone leads to down- 
regulation of CD46 by rapid internalization from the cell surface (Naniche et al. , 1993). This may 
affect or facilitate entry. Receptor-mediated endocytosis is probably not required for entry 
because the virus membrane is able to fuse with the cell membrane at neutral pH (Griffin and 
Bellini, 1996).
1.6 Replication of the virus
Replication of the measles virus occurs initially in the epithelial cells which line the buccal
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mucosa and the respiratory tract (Kempe and Fulginiti, 1965; Moench et al., 1988; Gellini and 
Katz, 1994b). Following replication in these tissues, it spreads to local lymphatic tissues where 
amplification occurs in the lymph nodes producing a primary viraemia. This results in the spread 
of the virus to multiple lymphoid tissues and other organs, including skin, kidney, gastrointestinal 
tract and liver (Kempe and Fulginiti, 1965; Modlin, 1991). Replication continues in endothelial 
cells, epithelial cells and monocytes/macrophages in these organs (Moench et al., 1988). The 
process of replication starts with the attachment of the virion to the cell membrane of the host 
cell, through a specific affinity between the viral envelope membrane protein, probably 
haemagglutinin, and a host cell receptor. Fusion of the viral envelope with the cell membrane 
follows, allowing the viral genome to penetrate the cell. This event is believed to be dependent 
on cleavage of the viral envelope F protein by a host cell enzyme and subsequent fusion activity 
by the activated F protein (Choppin et al., 1981; Modlin, 1991). Within a period of 24 hours 
following the penetration of measles virus genome into the host cells, viral RNA synthesis 
resumes (Portner and Bussel, 1973; Fournier et al., 1983).
Firstly, the negative stranded measles vims RNA is transcribed into a complimentary (positive) 
RNA message (Kingsbury, 1974; Modlin, 1991). The N gene is the first to be transcribed as the 
viral polymerase starts transcription at the 3' end of the virion RNA (Orvell, 1994). A 
transcription signal (gene-start) made up of 10 nucleotides is found at the 3' end of each of the 
genes to be transcribed. At the end of each gene, there is a termination sequence usually made 
up of 13 or 14 nucleotides. About 4 to 7 adenine molecules separates the termination signal from 
the intergenic sequence. The polymerase normally passes over this intergenic sequence to begin 
transcription at the next signal (i.e. the intergenic sequence is generally not transcribed by the 
polymerase). This facilitates the transcription of genes in a linear fashion (Orvell, 1994). From 
the resultant monocystronic mRNA various viral structural proteins are translated. This takes 
place on the polyribosomes. Formation of virion RNA also takes place here.
Membrane glycoproteins are then transported to the cell membrane through the endoplasmic 
reticulum and Golgi membranes. Complete cleavage of the F protein into FI and F2 is normally 
achieved after 5 hours. Although a portion of this protein may reach the cell surface uncleaved, 
uncleaved F is not incorporated into the mature virion (Orvell, 1994). The N can be found within
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the nuclei of infected cells, without any other viral structural protein being present. This is unique 
for measles virus and has not been reported for other paramyxoviruses (Orvell, 1994).
Transport of the M protein to the cell membrane is next. This protein lines the plasma membrane, 
where it interacts with the cytoplasmic tail of the envelope glycoproteins. One domain of the M 
protein interacts with the inner side of the cell membrane and another with the nucleocapsid 
(Orvell, 1994). Closely associated with the nucleocapsids intracellularly and in mature virions, 
are the actin filaments. These filaments assist in the formation of viral buds at the cell membrane. 
Normally, the entire process o f viral replication is completed approximately 20 hours following 
infection, and the infectious particles can be detected in the extracellular environment (Orvell, 
1994).
1.7 Biological characteristics of MV
1.7.1 Haemagglutination and Haemadsorption
A physiologic pH and a temperature of 37° C are required for haemagglutination to occur (Hirano 
et a l, 1992; Takenhara et al., 1992). The virus binds only primate erythrocytes and most 
efficiently agglutinates red blood cells from the African green monkey (Sheshberadaran et al., 
1983). This is consistent with the distribution of the CD46 molecule, which is absent on human 
but present on primate red blood cells (Liszewski and Atkinson, 1992). Cells infected with MV 
can be identified by their ability to adsorb monkey erythrocytes (haemadsorption). Both 
haemagglutination and haemadsorption are properties of the H glycoprotein (Hirano et al., 1992; 
Takenhara et al., 1992).
1.7.2 Fusion and Syncytia formation
The F glycoprotein is responsible for erythrocyte haemolysis and cell fusion. However, for the 
F glycoprotein to be optimally activated, the H glycoprotein is also required (Ruckle and Rogers, 
1957; Choppin and Scheid, 1980; Vialard etal., 1990; Wild etal., 1991; Takenhara et al., 1992; 
Cattaneo and Rose, 1993; Alkhatib et al., 1994). For example, cell to cell fusion requires the
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presence of both the H and F glycoproteins. A giant cell with many nuclei (multinucleated giant 
cell) occurs when infected cells fuse with uninfected cells. This can result in a syncytia 
comprising of 50 or more nuclei bounded by a single cytoplasmic membrane (Enders et al., 
1957). It has further been discovered that the treatment of cells with cytochalasin B prevents 
syncytia formation (Bedows et al., 1983). Lysis of agglutinated red blood cells follows a few 
hours after haemagglutination (Peries and Chancy, 1962).
1.7.3 Cvtopathic effects (CPE)
Cytopathic changes of three types accompany MV replication in cell culture monolayers of vero 
cells. These changes include the formation of multinucleated giant cells (syncytia), alteration of 
the cell shape and the formation of inclusion bodies (Enders et al. , 1957). The cells infected with 
MV may become stellate, dendritic or spindle in shape, and show increased refractility to light, 
compared to the normal polygonal shape they always display. This is normally the result of 
several stages of passaging (Milo vano vie e ta l, 1957; Seligman and Rapp, 1959). An observation 
that spindle cells occur particularly when high multiplicities of infection (Oddo et al., 1961) and 
complete medium (Reissig et al., 1956) are used, has led to the speculation that several stages 
of passaging may be related to the production of defective interfering particles (Mckimm- 
Breschkin et al., 1982).
1.7.4 Strain variation
MV virus is generally regarded as a stable virus. Sera from people who were infected decades 
ago easily neutralize the current wild-type MV strains. Those who have recovered from infection 
are immune for life (Griffin and Bellini, 1996). However, it is worth noting that the MV RNA- 
dependent RNA polymerase has an inherent error rate and no proofreading capacity, resulting 
in some degree of variability. Analysis of the nucleotide sequence of complementary DNAs has 
led to the description of such variabilities in the N, M, H and F genes (Taylor et al., 1991; Rota 
et al., 1992; Schulz et al., 1992; Sakata et al., 1993; Rota et al., 1994; Rima et al., 1995). 
Variability has also been described in the N, M and H proteins using monoclonal antibodies 
(Sheshberadaran and Norrby, 1986; Giraudon et al., 1988; Tamin et al., 1994).
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1.7.5 Virulence
Wild-type MV strains have been found to be much more virulent than vaccine strains. For 
example, when marmosets or tamarins are exposed to these two types of MV strains, those 
infected with the wild-type strain die, while those infected with vaccine strains do not (Albrecht 
et a i, 1980; Lorenz and Albrecht, 1980). However, it is important to note that infection of 
humans and macaques do not usually result in fatalities. It is believed that attenuation of 
virulence is associated with decreased virus replication in lymphatic tissue (Kamahora and Nii, 
1961; Ono et a i , 1970), diminished viraemia (Enders et a i, 1960; van Binnendijk et al., 1994), 
and failure to induce pathologic changes in neural tissue (Buynak et a i, 1962).
1.8 Pathogenesis and Pathology
1.8.1 Classic Measles
1.8.1.1 Transmission
Anyone infected with MV can transmit infection from as early as three days prior to onset of 
symptoms, until the rash desquamates (Gordon and Ingalls, 1954). It has been discovered that 
infectivity is at its highest during the prodrome phase, and decreases rapidly with the onset of the 
rash. The virus is spread by a respiratory route. Direct contact with respiratory secretions and 
exposure to aerosols created by coughing and sneezing, predisposes one to infection (Riley et a i , 
1978). In fact, aerosol spread is believed to be the most efficient way of transmitting measles. 
Also, a very low amount of infectious virus is sufficient to cause an infection in humans (Kress 
e ta i,  1961).
1.8.1.2 Incubation Period
Measles has an incubation period of 9 to 11 days. However, some prefer to measure it from 
exposure to the onset of the rash, in which case, it becomes 10 to 14 days (Christensen et ai, 
1952; Modlin, 1991). During this period, measles-related symptoms are not seen, except for the
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blood counts which may reveal leukopenia due to a low number of circulating lymphocytes 
(Benjamin and Ward, 1932; Black and Sheridan, 1960). This is a clear demonstration of the fact 
that the incubation period, is a time of active virus replication and proliferation (Modlin, 1991).
1.8.1.3 Prodromal Phase
Following the incubation period, the patient enters a prodromal phase which may last from two 
to four days. This phase is characterized by fever plus signs and symptoms of upper respiratory 
tract infection, including cough, coryza and conjunctivitis. Body temperature may reach 39 - 
40.5° C over a period of three to four days as fever becomes intense (Krugman et al., 1977; 
Modlin, 1991; Carter and ter Meulen, 1995).
Clinical
sym ptom s
conjunctivitis
cough
f e v e r
5 10 15 20
Days after infection
Fig. 1.2 : Clinical symptoms o f measles. Adapted from Griffin and Bellini, 1996
The patient is highly infectious at this stage since the virus is present or can be detected in the 
blood and secretions (Modlin, 1991). Respiratory symptoms also increase in severity during this 
phase. Small irregular bright red spots with a minute bluish-white spot in the middle, appear on
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the buccal mucosa and lower labial mucosa. They are called Koplik’s spots and are a certain sign 
ofmeasles (Koplik, 1896; Orvell, 1994; Carter and ter Meulen, 1995). These spots occur in more 
than 80% of cases (Gordon and Ingalls, 1954) and their presence is a useful diagnostic sign in 
the pre-emptive phase of measles since they do not occur in any other illness (Modlin, 1991). 
These spots begin to fade two to four days after the onset of the prodromal phase as the rash 
develops (Modlin, 1991; Orvell, 1994; Carter and ter Meulen, 1995).
1.8.1.4 Rash
Fourteen days following exposure, a distinctive maculopapular rash appears, first on the 
forehead, then behind the ears, and on the upper part of the neck. It then spreads gradually down 
the body, reaching the lower limbs and feet within 2 to 3 days (Modlin, 1991; Orvell, 1994; 
Carter and ter Meulen, 1995). See Fig 1.2. The fever peaks on the second or third day of the rash, 
and then diminishes rapidly, signalling clinical improvement (Modlin, 1991). Once the entire 
body is covered, the rash begins to fade on the third day or fourth day, and a brownish 
discolouration occurs, sometimes accompanied by a fine desquamation (Carter and ter Meulen, 
1995). The appearance of the rash is accompanied by a rapid decline in the amount of virus in 
the blood, such that MV is rarely recovered after the second day of the rash.
1.8.2 Atypical M easles
This type of measles is characterised by unusual clinical signs and symptoms, and is much more 
severe than classic measles. Signs and symptoms exhibited by people suffering from atypical 
measles include pneumonitis which is very severe and more frequent, severe skin lesions, and 
a high and more prolonged rash (Rauch and Schmidt, 1965; Nader et al., 1968; Rod et al., 1970; 
Young et al., 1970; Brodsky, 1972; Gremillion and Crawford, 1981). It has been seen in the 
recipients o f the inactivated measles vaccine used in the United States from 1963 to 1967 (Griffin 
and Bellini, 1996). Unlike in classic measles, the rash which is accompanied by evidence of 
haemorrhage or vesiculation, starts on the extremities and spreads to the trunk. Cases of atypical 
measles have been reported two to thirteen years after administration of formalin-inactivated 
vaccine (Welliver et al., 1977; Hall and Hall, 1979; Martin et al., 1979) and still may be 
occurring (Fomi et al., 1994).
15
1.8.3 Measles in the altered host
1.8.3.1 Immunosuppressed host
Measles can be prolonged or even be fatal in patients whose immunity is altered. These include 
patients who are or have been on chemotherapy or their immunity has declined due to 
malignancy or immunodeficiency. Severe measles has been reported in children with leukemia 
(Mitus et a l, 1959; Siegal et a l, 1977). Children infected with the human immunodeficiency 
virus (HIV) have been shown to be susceptible to severe and sometimes fatal measles infection, 
irrespective of whether they may have received live measles vaccine or recent immunoglobulin 
infusion (Linneman et a l,  1972; Centers for Disease Control, 1988).
Two studies reported a high death rate, due to measles, in infants infected with HIV (Diaz et al., 
1992; Oshitani et a l, 1996). It has also been noted that infection in early infancy is more 
common in these children (Embree et a l,  1992). The fact that measles can occur without the 
characteristic rash in HIV-infected individuals (Markowitz et a l,  1988), plus the fact that 
measles viral excretion can persist longer in these people (Scheifele and Forbes, 1972; Dossetor 
et a l ,  1977), suggest that transmission could be facilitated, especially in health-care settings. 
Prevention of measles is also disturbed by the fact that measles vaccine is less immunogenic in 
HIV-infected children. In a study conducted by Arpadi et al, 1996, in the USA, it was reported 
that the serological response to vaccine appeared to be lower the older the child at vaccination.
Another study done to measure antibody response to a standard measles vaccine in children from 
former Zaire vaccinated at 9 months of age, revealed that antibody response in HIV-infected 
infants was significantly reduced than that found in non HIV-infected infants (Oxtoby et a l, 
1989). Immunity in HIV-infected individuals appears to wane faster than in non-HIV-intected 
individuals (Al-Attar etal., 1995), and this is worsen by the fact that HIV-infected people whose 
measles-specific antibody had waned, respond poorly to a repeat dose of measles vaccine (Arpadi 
et a l, 1996). Death in patients who are immunocompromised is caused by giant cell pneumonia 
which may occur at any time from the incubation period (Mitus et a l, 1959) up to a year 
following the rash (Siegal et a l, 1977). Live measles vaccine has also been responsible for fatal
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giant cell pneumonia (Mitus et al., 1962; Mawhinney et al., 1971).
1.8.3.2 Measles in pregnancy
Once again, giant cell pneumonia has been described as the main cause of death during gestation. 
However, no link has been established between maternal measles and congenital anomalies 
(Dyer, 1940; Siegel, 1973; Jespersen et al., 1977). Several studies done have, however, shown 
that acute measles induces labour in 22 to 37 % of pregnant women, hence causing a high rate of 
spontaneous abortions and premature deliveries (Dyer, 1940; Siegel andFuerst, 1966; Jespersen 
e ta l, 1977; Gazelacfa/., 1985). Kohn etal, (1933) and Gazela etal, (1985), report that measles 
virus can infect the foetus in utero. It has also been discovered a measles infected mother going 
into labour during the incubation period will, at the same time as the infant, develop a rash, 
suggesting transplacental infection late in gestation (Kohn, 1933; Dyer, 1940). Some of these 
infants may develop a severe disease with pneumonia (Dyer, 1940). Mortality is approximately 
15%.
1.8.4 Subacute sclerosing panencephalitis (SSPE)
This is a very rare neurological disease, resulting from measles virus infection, affecting children 
and adolescents. Motor dysfunction, alteration in personality and mental deterioration, are the 
main characteristics of this disease. Other symptoms are convulsions, emaciation, coma, and 
death occurs within months to years following the onset of this disease (Freeman, 1969; Modlin, 
1991). Males are much more affected by this disease than females. Modlin, et al, (1979), report 
that SSPE occurs 2 to 3 times more frequently in males than females, and 3 to 4 times more 
frequently in whites than blacks in the United States. Majority of children show symptoms 
between the age of 5 and 14 years. Children acquiring measles at an early age and those from 
rural areas have been shown to be at a high risk of developing SSPE. The reason as to why this 
is the case, is still unclear at this stage (Jabbour et al., 1972; Modlin et al., 1979). Rapid 
deterioration of intellectual function, which may manifest itself in different ways, such as 
personality change, forgetfullness, poor attention span, difficulty sleeping and emotional lability, 
are the first signs of this disease (Freeman, 1969; Jabbour etal., 1969). Inafew cases, there may
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be some visual disturbances emanating from chorioretinitis (Robb and Walters, 1970; Font et 
a l,  1973). The patient may also exhibit sudden repetitive flexion movements in the extremities 
as often as 5 to 10 seconds. These movements, which do not interfere with the patient’s state of 
consciousness, and which normally disappear with sleep, represent myoclonic seizures (Modlin, 
1991). In the latter stages of the disease, cortical blindness occurs, and at this stage, intellectual 
function has been completely destroyed. The patient is at this stage showing signs of wasting, 
decerebrate posturing, as well as loss o f bowel and bladder control. Dysfunctioning of the 
hypothalamus is indicated by abnormal vital signs, such as abnormal blood pressure and 
respiratory rate, irregular pulse and high temperature. At this stage death is inevitable (Modlin, 
1991).
About 6 months to 3 years (mean : 24 months) following disease onset, death occurs (Case 
records of the Massachusetts General Hospital, 1974; Murphy e ta l,  1974). Although this disease 
has been treated with numerous therapeutic procedures, antiviral drugs and biologic agents, none 
has altered the course of the disease (Modlin, 1991).
1.8.5 Complications
Secondary bacterial infections involving the upper and lower respiratory tracts, giant cell 
pneumonia, acute measles encephalitis and rarely SSPE, are some of the complications which 
can occur in the normal host (Modlin, 1991).
1.8.5.1 Respiratory complications
Acute measles may predispose the lungs to secondary bacterial infection by the following 
bacteria: Streptococcus pneumoniae, Staphylococcus aureus or Neisseria meningitidis (Lucke, 
1918), and also by adenoviruses (Pather et al., 1976). It is also important to note that MV is 
capable of directly infecting the pulmonary parenchyma, producing (Hecht’s) giant cell 
pneumonia (Modlin, 1991).
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1.8.5.2 Gastrointestinal complications
Gastrointestinal symptoms is a result of epithelial surfaces being infected with MV (Morley, 
1969). Secondary bacterial and protozoal infections, are believed to be the cause of diarrhoea (De 
Mol etal., 1984; Greenberg etal. , 1991), a common complication of measles (Arya e ta i,  1987), 
especially in young children requiring hospitalization (Greenberg et a i, 1991).
1.8.5.3 Cardiovascular complications
Studies conducted by Cohen in 1963 and Finkle in 1964, indicate that death of the myocardium 
due to residual cardiac fibrosis of the conducting system (Giustra, 1954), occurs during the 
prodrome and acute phase of measles, and also some months later. Measles myopericarditis is 
also a complication of measles, although its occurrence is very rare. Degan, in 1937, discovered 
only two cases of measles myopericarditis and two additional cases of pericarditis in 100 autopsy 
specimens from patients who died during acute measles.
1.8.5.4 Neurological complications
Measles encephalitis complicates approximately one per 1000 cases of measles. This is an acute 
inflammatory reaction of the CNS associated with MV infection (Hoyne and Slotkowski, 1947; 
La Boccetta and Tomay, 1964; Measles encephalitis - United States, 1981). Vaccine 
administration is responsible for the decline in measles encephalitis which occurs in parallel to 
the declining incidence of measles, and as a result less than five cases are reported to the Centres 
for Disease Control each year (Measles encephalitis - United States, 1981).
1.9 Diagnosis
Most cases of measles are diagnosed on clinical grounds only. The following are clinical features 
characteristic of measles : fever (with temperatures of between 38.3° C and 40° C), erythematous 
maculopapular rash, coryza, cough, and Koplik’s spots (Griffin and Bellini, 1996). Not all of the 
above signs and symptoms may be present in one particular case. The fact that many of these are
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shared with other diseases, further serves to complicate matters (Makhene and Diaz, 1993). The 
CDC have devised their own clinical case definition of measles. It includes : a generalized 
maculopapular rash of 3 days or more; fever of 38,3° C (if measured); and one of the following 
signs and symptoms cough, coryza or conjunctivitis (Centers for Disease Control, 1983). The 
differential diagnosis includes scarlet fever, toxic shock syndrome, rubella, parvovirus B19 
infection, meningococcemia, Kawasaki disease, dengue, and perhaps other as yet unidentified 
infections (Brown et al., 1994).
MV can be isolated from a number of sources, such as throat swabs, conjunctival washings, 
sputum, urinary sediment cells and lymphocytes. Multinucleate giant cells with inclusion bodies 
are characteristic of measles. These cells are detectable in the nasopharyngeal secretions (NPS) 
during the prodromal phase (Carter and ter Meulen, 1995). The direct and indirect 
immunoflourescence (IF) have been used extensively. Both these techniques are applicable to 
cells shed in nasal secretions, although removal of antibodies already coating the virus antigens 
may be necessary. IF is useful for the diagnosis of measles in the pre-eruptive phase or in 
children vaccinated with killed vaccine, where rash development is atypical (Carter and ter 
Meulen, 1995).
Measles diagnosis is most often confirmed by serology. Enzyme immunoassay (EIA) is the best 
serological technique for the fact that it allows for differential detection of IgM and IgG, and its 
convenience when large numbers of samples are involved. As a result, this technique is widely 
used. Normally acute and convalescent serum pairs are the best samples to consider. Detection 
of MV-specific IgM antibodies in serum or saliva is diagnostic (Sabin, 1991; Perry et a l, 1993; 
Brown et a l, 1994) and may require a single sample (Griffin and Bellini, 1996). IgM antibodies 
appear at the time of the rash and can be detected 3 days after the onset of the rash in most 
individuals (Rossier et a l, 1991; Perry et al., 1993).
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1.10 Prevention and control
1.10.1 Prophylaxis
Immune serum globulin (ISG) is capable of preventing or modifying measles if given to children, 
up to six days following exposure (Ordman et al., 1944). The target group should be children 
under 1 year of age, because of a high risk of complications in this age group. Intravenous 
immune globulin (1VIG), has also been used. This immune globulin contains a high titre of 
measles antibody. It has, however, been implicated in one case of fatal measles infection, after 
it had been regularly administered to an HIV-infected patient (Markowitz et a l, 1988).
1.10.2 Treatment
No standard antiviral treatment exists for measles. However, several studies report that Ribavirin 
has shown encouraging results, particularly in the reduction of the severity of symptoms in acute 
measles (Uylangco et a l, 1981), and inhibition of viral replication in vitro (Hosoya et al., 1978; 
Murphy, 1978; Shigeta etal., 1992). Some studies have also shown that when vitamin A is given 
in high doses during acute measles, even in the absence of clinical evidence of vitamin A 
deficiency, there is a significant decrease in morbidity and mortality (Fulginiti et al., 1967; 
Barclay et a i, 1987; Coutsoudis e ta l ,  1991; Coutsoudis etal., 1992).
1.10.3 Vaccination
1.10.3.1 History
Credit must go to Home (1759), for the his earliest attempts at vaccination against measles. From 
the observation that measles infection caused severe pulmonary symptoms, he concluded that the 
effects on the lung could be lessened by introducing the disease through the skin. There were 
other attempts between 1920 and 1940 by various groups of researchers, in which attempts were 
made at inactivating or culturing the virus in chick embryos. These, also, did not yield much 
success (Hektoen, 1905; Savini, 1923; O ’Neil et a l,  1940; Ritossa and Mule, 1941). It is the
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isolation of MV in culture which opened the way for a more concerted approach to vaccine 
development, with the Edmonston strain playing a key role (Enders and Peebles, 1954).
1.10.3.2 Vaccines
(A) Killed vaccine
This vaccine which contained the Edmonston MV strain, and commonly used in the United 
States of America, was obtained by subjecting the strain to formalin treatment with alum as an 
adjuvant (Warren and Gallian, 1962). Reports received from field trials, indicated that children 
who received this vaccine, lost antibodies to measles rapidly, and that the protection conferred 
by this vaccine waned over 3 years in 50% of the recipients (Fulginiti and Kempe, 1963; 
Winkelstein et al., 1965). Some recipients acquired clinical infection, while some developed 
atypical measles syndrome upon exposure to natural measles (Karzon et a i, 1965 Rauch and 
Schimidt, 1965).
(B) Live-attenuated vaccine (Edmonston B)
Edmonston B vaccine, was the first live attenuated measles vaccine to be developed, by 
adaptation of the Edmonston MV strain to chick embryos, and subsequently to chick embryo 
fibroblasts. These were done after this strain was passaged 24 times in primary renal cells and 
primary amnion cells, (Katz et al., 1958; Enders et al., 1962). This vaccine was then tested in 
monkeys, where it induced antibody and protected the animals from subsequent challenges with 
low-passage Edmonston virus (Modlin, 1991). Seroconversion rates of more than 95% were 
recorded in trials conducted in institutionalized and home-dwelling children. Also antibody 
persistence and protection against natural infection were shown in these trials (Katz and Enders, 
1959; Black and Sheridan, 1960; Katz et al., 1960a; Katz et al., 1960b; Kempe et al., 1960; 
Kress et al., 1961; McCrumb et al., 1961; Katz et al., 1962).
(C) Further live-attenuated vaccines
Schwarz vaccine, a more attenuated vaccine developed by Schwarz tlirough further passaging
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the Edmonston B virus in chick embryo fibroblasts (Schwartz, 1962), is currently the standard 
measles vaccine worldwide. This vaccine was licensed in 1965 (Griffin and Bellini, 1996). 
Another more attenuated vaccine, the Moraten strain which is closely related to the Schwarz, was 
licensed in US in 1968 (Rota et al., 1994). Like the Schwarz strain, the Moraten strain was also 
obtained by additional passaging of the Edmonston B strain in chick embryo fibroblasts. Other 
further live-attenuated measles vaccine, also derived from the Edmonston B virus like 
Edmonston-Zagreb are used in certain parts of the world (Cutts et al., 1994). This vaccine was 
obtained by passaging the Edmonston B strain 19 times in human diploid cells (Markowitz and 
Bernier, 1987).
1.11 Epidemiology
Measles occurs in every part of the world inhabited by man. This highly contagious 
communicable disease is transmitted efficiently through the respiratory route (Hope-Simpson, 
1952). The absence of an animal reservoir or evidence of latent or epidemiologically significant 
persistent infection, implies that its maintenance in the population depends solely on the 
availability of susceptible people. It is primarily a childhood disease, the reason being that older 
individuals had been previously exposed to the virus, and as such have become immune to 
infection (Black, 1975). This disease can occur at any time of the year, although a marked 
seasonal variation has been noticed in endemic areas. In temperate climate, for example, it has 
been reported that morbidity due to measles increases during the months of October and 
November, the period of onset of cooler weather and the opening of schools. The opening of 
schools and indoor overcrowding during colder weather, provide opportunities for transmission 
(Gordon and Ingalls, 1954). Added to this is the fact that during winter, the lower humidity that 
prevails indoors, enhances the ability of measles to survive (De Jong and Winkler, 1964). It is 
reported to be very high between February and April (Modlin, 1991). Passively acquired maternal 
measles antibody protect the infant from measles during the first six months of its life. These 
antibodies begin to wane after this period, and the infant may later become susceptible to 
measles. Opportunity for contact with a contagious person determines the age of infection, 
beyond the first year of life. There is no correlation between susceptibility to measles virus and 
age (Modlin, 1991). Measles transmission depends on the number of individuals in a population 
and their opportunities for contact with the disease.
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1.12 Immune responses
Several clinical manifestations of measles are due to immune responses to MV. These immune 
responses are important for two reasons, namely clearance of MV and recovery from infection. 
During the incubation period, the non-specific host immune responses play a major role in 
controlling the replication of the virus. MV-specitic immune responses appear with the onset of 
clinical disease (Griffin and Bellini, 1996). At this stage, there is spontaneous proliferation of 
peripheral blood mononuclear cells (PBMCs) (Besser et a l , 1967; Ward et a l , 1990), polyclonal 
activation of B cells (Griffin et a l, 1985), expression of activation antigens on T cells (Griffin 
et a l, 1986), and increased plasma levels o f cytokines and soluble surface proteins (Griffin eta l, 
1989; Furukawa et a l, 1992; Griffin et a l,  1992). These are clear signs of activation of the 
immune system At the same time as activation occurs, immune suppression appears, and both 
can continue for many weeks after recovery from measles (Griffin and Bellini, 1996).
1.12.1 MV-specific immune responses
1.12.1.1 Humoral immunity
In naturally infected people, MV antibodies are detectable in serum shortly after the onset of rash 
(Ruckle and Rogers, 1957). For those who have received a live attenuated measles vaccine, 
antibodies are detectable 11 to 14 days after vaccination (Krugman et a l , 1965). IgM antibodies 
are the first to be detected, and will last for 3 to 6 weeks (Schluederberg, 1965; Lievens and 
Brunell, 1986). IgG antibodies appear later than IgM antibodies, peak in 2 to 6 weeks, and 
gradually decline to low but persistent levels, for life. A boost in titre of IgG occurs during 
reinfection, but IgM antibodies do not reappear (Scliluederberg, 1965). As a result, immune 
children exposed to natural infection would maintain higher levels of antibody as a result of 
subclinical reinfections, than do immune children who do not have opportunities for reinfection 
(Krugman et a l, 1965). Secretory IgA antibody is induced by both the natural infection and 
infection with attenuated vaccine virus (Bellanti et al., 1969).
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As far as induction of antibody production is concerned, the N protein seems to be the most 
effective as witnessed by the most abundant and most rapid production of antibody to this protein 
(Norrby and Gollmar, 1972; Graves etal., 1984). Because of the abundance of this antibody, its 
absence is a reliable indicator of seronegativity (Griffin and Bellini, 1996). The M protein elicits 
only small amounts of antibody, except in atypical measles (Machamer et al., 1980; Graves et 
al., 1984). Antibodies to F protein may contribute to virus neutralisation by preventing fusion 
of the virus membrane with the cell membrane at the time of virus entry (Malvoisin and Wild, 
1990). They can be measured in two ways; first by haemolysis of monkey erythrocytes by MV 
(haemolysin inhibition)(Norrby and Gollmar, 1972) or by immunoprecipitation of the protein 
(Norrby and Gollmar, 1975). Measurement of antibodies to the H protein is achieved by 
inhibition of monkey erythrocytes by MV (haemagglutination inhibition)(Norrby et al., 1965; 
Giraudon and Wild, 1981). These antibodies are also capable of inhibiting haemolysis (Norrby 
and Gollmar, 1972; McFarlin etal., 1980; Carter etal., 1982) and are also the primary antibodies 
measured by neutralization of virus infectivity in tissue culture (McFarlin et al., 1980; Giraudon 
and Wild, 1981; Giraudon and Wild, 1985), although antibodies to F do have some neutralizing 
activity as well (Varsanyi et al., 1984).
In addition to protection from MV infection (Krugman, 1963; Albrecht etal., 1977;Black, 1989; 
Siber etal., 1993), antibodies contribute to recovery from infection (Lin and Hsu, 1986), and may 
also play a major role in establishing persistent infection (Rammohan et al., 1982). Evidence 
suggests that when antibodies bind to infected cells, they alter the replication of virus in the cell 
and by so doing contribute to the control of infection (Fujinami and Oldstone, 1979; Fujinami 
and Oldstone, 1980; Schneider-Schaulies et al., 1992). Therefore, failure to mount an adequate 
antibody response carries a poor prognosis (Wesley et a l, 1982).
1.12.1.2 Cell-mediated immunity
When lymphocytes from individuals immune to measles, are exposed to MV antigen (Graziano 
et a l, 1975; Gallagher et al., 1981), they undergo transformation and kill MV-infected tissue 
culture cells (Labowskie et al., 1974). According to Burnet (1968), the ability to recover from 
measles is an indication of the adequacy of T-lymphocyte-mediated immune responses. MV-
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specific, HLA-restrictedCD8+ cytotoxic T-lymphocytes(Kreth etaL, 1979; Sissons etal., 1985: 
van Binnendijk et a l ,  1990), and proliferating CD8+ T cells (Ward et a l ,  1990) are detectable 
in blood at the time o f the rash and in broncho alveolar lavage fluid during pneumonitis (Myoi 
et a l ,  1993). When cells are infected with MV in vitro, MHC class I expression is up-regulatec 
through the production o f IFN-P (Dhib-Jalbut and Cowan, 1993), and if this process also take; 
place in vivo, it may enhance recognition o f MV-infected cells by CD8+ T cells (Griffin anc 
Bellini, 1996).
MV-infection activates CD4+ T cells as well. Proliferation o f these CD4+ T cells occurs during 
the rash (Ward et aL, 1990), and soluble CD4 becomes elevated and remains so for several week 
(Griffin and Ward, 1993)( Fig. 1.3). In people who are immune to measles, MV proteins ca] 
induce lymphocyte proliferation (Rose et a l ,  1984; Pette et a l ,  1993), and this proliferation ha 
been shown to be MHC class II-restricted (CD4+ cells), and to occur in response to purified H 
N, P, F and M proteins (Bellini et a l,  1981; van Binnendijk et al. , 1993).
Flg.1.3 : Levels o f  cytokines and soluble (s) cell surface molecules in the blood during
uncomplicated measles. These patterns indicate early CD8+ and type 1 CD4+ T-cel 
activation, followed by type 2 CD4+ T-cell activation (see text). Adapted from Griffii 
and Bellini, 1996.
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As depicted in Fig. 1.3, circulating levels of cytokines produced by activated T cells and 
macrophages are high during measles. First to be elevated are IFN-y, neopterin (a product of 
activated macrophages), and soluble IL-2 receptor. These are elevated during the prodrome, 
before the appearance of a rash (Griffin et al., 1989; Griffin et al., 1990). Next to be elevated, 
are IL-2, soluble CD4, and soluble CD8 at the time of the rash (Griffin eta l, 1989; Griffin et al., 
1992). 1L-4 levels are raised as the rash fades, and they may remain elevated for weeks in some 
people (Griffin et al., 1992).
1.12.1.3 Immunity to reinfection
Infection with MV confers lifelong immunity to symptomatic reinfection (Modlin, 1991). The 
long-term protection from reinfection following recovery from measles does not require re­
exposure to the virus (Panum, 1939). Immunologic memory includes both continued production 
of antibody (Black and Rosen, 1962) and circulation of MV-specific T cells (Lucas etal., 1982; 
van Binnendjik et al., 1990; Wu et al., 1993). Reports have been received of measles occurring 
in people previously infected with the virus, however, these are poorly documented (Watson, 
1965). There have been reports of subclinical reinfection in children who have been infected 
naturally, or who are recipients of a measles vaccine (Krugman et al., 1965; Linneman et al., 
1973). Two features clearly define subclinical reinfection. These are absence of IgM antibodies 
(Linneman et a i, 1973) and an anamnestic lgG antibody response (Linneman et al., 1972).
1.12.1.4 Recovery from natural infection
The cell-mediated immune response appears to play a key role in recovery from MV infection. 
Failure to mount an adequate immune response, as seen in patients with Acquired 
immunodeficiency syndrome (AIDS) (Markowitz et al., 1988; Centers for Disease Control, 
1988), in congenital immunodeficiency syndromes (Nahmias et a l, 1967), immunosuppressive 
chemotherapy (Mitus et al., 1959) and in the presence of malnutrition (O’Donovan, 1971) can 
lead to severe, and sometimes fatal, measles virus infections (Modlin, 1991). Good and Zak, 
(1956), and Ruckdeschel et al (1975), report that patients with isolated agammaglobulinaemia, 
and otherwise normal persons who have undetectable antibody responses to measles, handle
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acute infection in the normal fashion and are immune to clinical reinfection.
1.12.1.5 Immune suppression
Measles is accompanied by immune suppression. This is supported by both in vitro and in vivo 
evidence. This suppression is thought to contribute to the susceptibility to secondary bacterial 
infections which have been implicated in most of the morbidity and mortality associated with 
MV infection (Miller, 1964; Morley, 1969; Beckford et ah, 1985). In vitro studies reveal 
abnormal lymphokine production (Joffe and Rabson, 1981; Crespi et a l, 1988; Ward et al., 
1991) and suppressed lymphoproliferative responses to mitogens (Arneborn and Biberfeld, 1983; 
Hirsch et al., 1984). Further analysis of in vitro abnormalities has shown that there may be 
defects in the responses of both the monocytes and lymphocytes (Griffin and Bellini, 1996).
Several in vivo studies reported that delayed type hypersensitivity skin test responses to recall 
antigens, such as tuberculin, are suppressed before the rash and for several weeks after apparent 
recovery from infection (von Pirquet, 1908; Starr and Berkovich, 1964; Wesley et al., 1978; 
Tamashiro et a l, 1987). There is also evidence of impairment of antibody production and cellular 
immune responses to new antigens (Coovadia et a l, 1974; Whitley et al., 1982). Infection of 
monocytes by MV is believed to be responsible for the alteration of its function or cell lysis, or 
both (Esolen et al., 1993; Griffin et al., 1994). When macrophage lineage cells are infected with 
measles virus in vitro, IL-1 increases and tumour necrosis factor-a (TNF-a) decreases, implying 
that these abnormalities are a direct result of infection (Leopardi et al., 1992). Deficient 
production of TNF-a, a pro inflammatory cytokine, may contribute to decreased 
lymphoproliferation in vitro, and may blunt responses to new infectious challenges in vivo 
(Griffin et al., 1992). T cell levels are low during measles, although normal proportions of CD4+ 
and CD8+ T cells are maintained (Arneborn and Biberfeld, 1983; Griffin et al., 1985). One factor 
contributing to a low T cell count, is insufficient production of IL-2. This is supported by the 
observation that when recombinant IL-2 is added to cultures, there is spontaneous proliferation, 
and mitogen responses are improved (Griffin et al., 1986; Ward and Griffin, 1993).
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Changes have also been detected in the level of other cytokines such as IL-4 which may be raised 
compared to controls, and IFN-y which may be low to normal (Crespi et al., 1988; Ward et al., 
1991; Griffin and Ward, 1993). In addition to providing help for B cells, IL-4 stimulates growth 
and differentiation of type 2 CD4+ T cells but down-regulates the responses of type 1 CD4+ T 
cells and deactivates macrophages. In these ways, it serves as a general suppressant of 
macrophage activation and DTH responses and may be one of the mechanisms by which in vivo 
tuberculin responses and in vitro lymphoproliferative responses are suppressed during measles. 
These abnormalities of macrophage and T cell function may increase susceptibility to other 
infections (Griffin et al., 1994).
1.12.1.6 Autoimmunity
About one in a thousand cases of measles may lead to encephalomyelitis. This usually occurs 
in older patients (Miller, 1964), about 14 days following the appearance of a rash (Litvak et al., 
1943). Johnson et al.{ 1984), report that the immune response to the myelin basic protein is 
induced, resulting in demyelination. This induction of the immune response to the myelin basic 
protein suggests that this is an autoimmune disease.
1.12.2 Non-specific immune responses
As mentioned earlier on, non-specific host immune responses play a major role in controlling 
viral replication during the incubation period. Furthermore, non-specific immune responses also 
play an important role in protecting the MV-infected host from secondary microbial infections.
1.12.2.1 Cytokines
Two cytokines, interferon-a (IFN-a) and interferon-p (IFN-P) are produced when cells are 
infected by MV in vitro (Volckaert-Vervliet and Billiau, 1977; Jacobson and McFarland, 1982). 
IFN-a slows down the replication of MV, and IFN-P increases the expression of the major 
histocompatibility complex (MHC) class I antigen on infected cells (Jacobson and McFarland, 
1982; Dhib-Jalbut and Cowan, 1993). It has been reported that 8 to 11 days following
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immunization, increased levels of 1FN are present in serum (Petralli et a l,  1965), but during 
natural infection, elevated plasma levels of biologically active IFN have not been documented 
(Shiozawa et al. 1988; Griffin et al., 1990).
1.12.2.2 Natural killer (NK) cells
Other cells worth mentioning, which may form part of the early defence mechanism, are the 
natural killer (NK) cells. Studies conducted on these cells indicate that their function is lower 
than normal during measles (Griffin e ta l, 1990). However, these studies were done using human 
samples collected at the time of the rash and hence do not exclude induction of and roles for IFN 
and NK cells at earlier stages of infection (Griffin and Bellini, 1996).
1.12.2.3 Polymorphonuclear leukocytes (PMNL)
PMNL are the principal cells involved in the immune response to invasion of the host by bacteria 
and fungi (Abramson and Mills, 1988). Although the role of these cells in controlling viral 
infections is usually less important than that of mononuclear cells, the PMNLs are usually the 
first to be recruited to the site where there is invasion by microbes, and there they accumulate in 
large numbers, serving as the principal cell involved in the killing of these pathogenic organisms 
(Abramson and Wheeler, 1994).
These cells are also called polymorphonuclear granulocytes or granulocytes or polymorphs. As 
their name suggests, they have multilobed nuclei and contain many granules in their cytoplasm. 
They represent 60% to 70% of peripheral white blood cells. Their granules stain differently with 
histological dyes, and it is on this basis that they have been subdivided into neutrophils, 
eosinophils and basophils. Neutrophils are by far the most abundant, making up more than 90%- 
95% of circulating granulocytes. Hence the term polymorphonuclear leukocytes has become 
synonymous with neutrophils.
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(A) Normal function of PMNL
As mentioned above, PMNLs are the first cells to arrive at the site o f bacterial infection. 
Following invasion o f the host by bacteria, chemotactic stimuli (e.g. bacterial peptides) are 
released and attach to specific receptors on the PMNL outer membrane. Occupation o f receptors 
by a stimulus initiates the transduction o f a signal, a sequence o f biochemical steps collectively 
called the activation pathway. This in turn results in the end stage functions allowing for the 
ingestion, killing and degradation o f the organism (Abramson and Wheeler, 1994). See Fig. 1.4 
below.
There are a number of activation pathways and those that are activated depend on the specific 
type o f receptor that is engaged by the stimulus. Engagement o f a receptor by a ligand results in 
enhancement o f G protein activity (G proteins link receptors to the initial enzyme that starts the 
activation pathway), changes in the concentrations o f second messengers (e.g. cyclic adenosine 
3',5'-monophosphate, calcium), phosphorylation/dephosphorylation o f intracellular proteins and
Fig. 1.4 : Neutrophil chemotaxis. Adapted from Peakman and Vergani (1997).
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alterations in the structure o f the cytoskeleton. Chemotactic activity occurs within one minute 
o f the binding o f the ligand to the receptor and is usually the first end stage function to occur. 
During the chemotactic process PMNL in the blood adhere to vascular endothelium and then 
migrate through the endothelial cell junction to the site o f invasion.
Once at the infected area, opsonized microbes (Fig. 1.5) become bound to the cell by specific 
receptors (e.g. Fc antibody receptors and complement receptors). This new receptor-ligand 
interaction initiates an activation pathway similar although not identical to the signal induced by 
stimuli causing chemotaxis (Abramson and Wheeler, 1994).
Bactenum
Fig. 1 .5: Opsonisation. Opsonins coat microorganisms and enhance the neutrophils’ ability to 
engulf them. Adapted from Peakman and Vergani (1997).
Subsequently, the bacteria are phagocytosed, a process in which organisms are taken up in large 
intracellular plasma membrane-bound vacuoles known as phagosomes. Secretory activities then 
occur in which three types o f lysosomal granules (Le. primary, secondary and tertiary), each 
containing a variety o f enzymes, fuse with phagosomes and other cellular plasma membrane 
sites. This process results in the release o f enzymes into intracellular and extracellular spaces and 
causes killing and degradation o f bacteria. Simultaneously, the oxidative burst is activated, 
producing oxygen radicals lethal to bacteria (Abramson and Wheeler, 1994). See Fig. 1.6.
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Fig. 1.6 : Phagocytosis: (a) Opsonized bacterium binds to neutrophil, (b) Pseudopodia extend 
around the bacterium, (c) Bacterium is engulfed inside a phagosome to which granules fuse and 
release their contents. Adapted from Peakman and Vergani (1997).
(B) Virus-induced alteration of PM NI. function
Evidence from previous studies, indicate that viruses can predispose humans to secondary and 
systemic bacterial and fungal diseases. Several viruses have been implicated in the depression 
o f various functions of PMNLs. These viruses include Influenza, Cytomegalovirus (CMV), HIV, 
and many others (Abramson and Wheeler, 1994).
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A large number of in vitro and in vivo studies involving animals and humans indicate that 
Influenza A virus has an immunosuppressive effect on PMNLs. PMNL dysfunction precedes and 
predisposes to the development of secondary disease in animals infected with Influenza A virus 
(Abramson et al., 1981; Abramson et al., 1982). In general, the studies have shown that Influenza 
A virus decreases PMNL oxidative, ehemotactic, secretory and bactericidal activities whereas 
phagocytosis remains unaltered. These data support the concept that virus-induced neutrophil 
dysfunction has an important role in the development of superinfections (Abramson and Wheeler, 
1994).
A report by Bale et al. (1982), indicated that PMNL functions are depressed in animals 
undergoing primary CMV infection. One study reported a decrease in the mobilization of PMNL 
to inflammatory sites in the guinea pig with primary CMV infection, which correlated with 
decreased release of hydrogen peroxide and decreased bacterial intracellular killing by peritoneal 
PMNL (Yourtee et al., 1982). In addition, de novo appearance of both PMNL-directed and 
chemotaxin-directed plasma inhibitors has been noted during early CMV infection in guinea pigs 
(Tannous eta l ,  1979).
HIV-induced PMNL dysfunction has been implicated in the increased risk of bacterial infections 
in HIV-1 infected individuals (Pitrak et al., 1993). The variance in altered PMNL functions 
reported in several studies suggests that the type of PMNL dysfunction might depend on a 
number of factors including the stage of HIV disease and whether there are concomitant 
infections that also cause PMNL dysfunction (e.g. CMV) (Abramson and Wheeler, 1994).
(C) PMNL and Measles virus
Patients infected with MV, have been found to be at greatly increased risk of developing 
respiratory infections caused mainly by Staphylococcus aureus and Mycobacterium tuberculosis 
(McChesney and Oldstone, 1989; Aaby et al., 1991). A team of researchers led by Anderson 
(Anderson et al., 1976), reported that a more important cause of morbidity and mortality in 
patients with measles, was the secondary bacterial infection caused by bacteria against which 
PMNL are directed. These researchers demonstrated a severe defect of both directional and non­
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directional movement of PMNL cells of all patients with measles. The chemotactic defect was 
not only demonstrated in an in vitro system, but was also substantiated by grossly impaired 
neutrophil accumulation in Rebuck skin windows. They further reported that this chemotactic 
defect in PMNL of patients with measles was not due to serum inhibitors. Without discounting 
the importance o f local effects of the MV, it was suggested that a severe chemotactic defect, 
similar to the one they have described in their study, could play an important role in accounting 
for the frequency of occurrence and the severity of secondary bacterial infections (Anderson et 
al., 1976).
1.13 Apoptosis
Apoptosis, also called programmed cell death, is the process whereby individual cells of 
multicellular organisms undergo systematic self-destruction in response to a wide variety of 
stimuli (Teodoro and Branton, 1997). Most, if not all animal cells have the ability to self-destruct 
by activation of an intrinsic cell suicide program when they are no longer needed or have become 
seriously damaged. The execution of this death program is often associated with characteristic 
morphological and biochemical changes (Wyllie et al., 1980). Apoptosis is a genetically 
controlled preprogrammed event which eliminates cells during development when they have 
become redundant or which functions as an emergency response after radiation damage, viral 
infection, or aberrant growth induced by the activation of oncogenes. In the case of virus-infected 
cells, the induction of early cell death would severely limit virus production and reduce or 
eliminate spread of progeny virus in the host. Thus most animal viruses have evolved strategies 
to evade or delay ear ly apoptosis to allow production of high yields of progeny virus (Teodoro 
and Branton, 1997).
A variety of physiological and non-physio logical stimuli can provoke apoptotic cell death, among 
them, metabolic stimuli disturbances due to chemical insults, virus infections or developmental 
cues (Vaux and Strasser, 1996). Although not all signals which initiate the apoptosis pathway 
are understood, in many, but not all, cases the tumour suppressor protein p53 is required to 
propagate the signal to commit suicide (Levine, 1997). Members of the Bcl-2 family represent 
a major set point in the apoptotic pathway with cell fate resting, in many cases, with the dynamic
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balance between family members which promote and inhibit apoptosis (White, 1996; Rao and 
White, 1997). Bcl-2-like family members appear to sit at a node in the apoptotic pathway at a 
point of integration for stimuli which provoke apoptosis and, in many but not all cases, appear 
to influence the activation of caspase family members [IL-ip-converting enzyme (ICE)-like 
proteases] which perform the ‘execution’ phase of apoptosis, cleaving a number of cellular 
proteins to bring about destruction of cell structure (Clem and Duckett, 1997; Nagata, 1997; Rao 
and White, 1997).
Apoptotic cell death is characterised by controlled autodigestion. Cells appear to initiate then- 
own apoptotic death through the activation of endogenous proteases (Thompson, 1995). The 
process is characterized by a number of distinct morphological features and biochemical 
processes. These include cytoskeletal disruption, cell slirinkage and partial detachment from 
substratum and plasma membrane blebbing (Vaux and Strasser, 1996; White, 1996).
Apoptosis also involves characteristic changes within the nucleus. The nucleus undergoes 
condensation as endonucleases are activated and begin to degrade nuclear DNA. In many cell 
types, DNA is degraded into DNA fragments the size of oligonucleosomes, whereas in others 
larger DNA fragments are produced. Apoptosis is also characterised by a loss of mitochondrial 
function. This has led to speculation that mitochondria may have an important function in 
regulating apoptosis; however, data to support this hypothesis are currently unavailable.
The dying cell maintains its plasma membrane integrity. However, alterations in the plasma 
membrane of apoptotic cells signal neighbouring phagocytic cells to engulf them and thus 
complete the degradation process (Thompson, 1995). Cells not immediately phagocytosed break 
down into smaller membrane-bound fragments called apoptotic bodies. An important feature of 
apoptosis is that it results in the elimination of the dying cell without induction of an 
inflammatory response (Thompson, 1995).
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1.14 Objectives of this study
MV-infected persons have been found to be at a greatly increased risk of developing respiratory 
infections caused mainly by Staphylococcus aureus and Mycobacterium tuberculosis. PMNL 
play an important role in combating primary and secondary bacterial and fungal infections. It has 
been reported that secondary bacterial infections are an important cause of morbidity and 
mortality in patients with measles.
The only study we know of, to date, that has addressed the effects of MV on PMNL, is the one 
conducted here in South Africa by a group of researchers led by Anderson (Anderson et al., 
1976). Neutrophils isolated from MV-infected children were shown to be defective for 
chemotaxis. It was, however, not established in that study whether MV, directly or indirectly, was 
the cause of this defect.
The main question being addressed in this study is whether MV has any direct effects on PMNL 
functions that could account for the increased susceptibility of MV-infected persons to secondary 
microbial infections.
The objectives of this study, therefore, were
(a) To determine which, if any, PMNL functions (i.e. chemotaxis, phagocytosis, 
degranulation and oxidative burst), are altered by exposure to MV in vitro.
(b) To determine whether MV can, directly or indirectly, induce apoptosis in vitro.
(c) To determine whether virus attenuation or heat inactivation of MV strains have any effect 
on these functions.
(d) To determine whether ligation of the MV-specific receptor, CD46, by CD46 antibody can 
alter any of the PMNL functions mentioned above.
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CHAPTER 2
MATERIALS AND METHODS
2.1 PREPARATION OF VIRAL STOCKS
Reagents
Viral seed stocks 
Cell line (Vero)
RPMI 1640
Foetal Calf Serum (FCS)
Viral seed stocks and vero cells that were used for the purpose of this study were obtained from 
the Measles Unit of the National Institute for Virology (NIV). The stocks had been stored in 1 
ml aliquots at -70°C.
2.1.1 Trypsinization of vero cells
Vero cells, once confluent were trypsinized as follows : the supernatant was poured off a T150 
flask (tissue culture flask with area of 150 cm2) containing vero cells. 5ml of trypsin was added 
to the flask to loosen cells attached to the flask. The flask was then placed in the hood for 5 
minutes, after which 8 ml of medium (RPMI 1640 + 4% FCS) was added to wash off the cells 
and trypsin. The contents of the flask were then transferred to a falcon tube, and centrifuged in 
a Sigma 4K15 centrifuge (Laborzentrifugen GmbH 37520 Osterode)for 5 minutes at 1000 rpm 
(rotor 11150). After discarding the supernatant, the pellet was resuspended in 14 ml RPMI 1640 
+ 4% FCS. To each of the 4 T75 flasks, 4 ml of the cell suspension was added, and made up to 
35 ml, in each flask, with RPMI 1640 + 47c FCS. The flasks were then placed in an incubator 
at 37° C (5% C 0 2), and monitored over a number of days for confluency.
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2.1.2 Inoculation of vero cells with MV strains
Three different measles virus strains representing different degrees o f attenuation were used for 
cell inoculations. These were the Schwartz (SCH) strain (a vaccine strain), Johannesburg 25 
(JHB 25) strain (a vaccine-like strain) and a strain designated D1317 (a wild-type strain). After 
establishing that the vero cells were almost confluent, the supernatant was poured off, and 1 ml 
of the virus stock added. The supernatant in another flask (uninfected control) was discarded and 
fresh medium added. The cells were then placed in an incubator at 37° C (5% C 0 2), and checked 
daily for cytopathic effect (CPE) over a number of days. MV infections were graded according 
to the CPE of the cells at the time of harvesting. The grading was as follows : + = CPE of about 
20% - 30%; ++ = CPE of 50% - 60%; +++ = CPE of 70% - 80% , and ++++ -  CPE of 90% - 
100% .
2.1.3 Harvesting of viral stocks
Virus stocks were immediately harvested when all flasks o f cells for each MV strain showed a 
CPE of ++++ (90% - 100%). This was done to ensure that all stocks o f virus strains were 
approximately similar in concentration. That stock viruses were of equivalent infectivity, was 
confirmed by the fact that when used at the same dilution to infect vero cells, gave rise to the 
production of CPE at a similar rate. Cells still attached to the flask were gently scraped off with 
a cell scraper. The contents of each flask were transferred to a 50 ml falcon tube, and centrifuged 
at 1000 rpm, for 5 minutes, at 4° C. The supernatants were then discarded, and the pellet in each 
tube was resuspended in 14 ml RPMI 1640 + 4% FCS. These cell suspensions were then stored 
in aliquots of 1 ml in 1.5 ml nunc tubes, at -70° C.
2.1.4 Heat-inactivation of viral stock preparations
A proportion of each of the viral stocks prepared above were incubated in a 56" C water bath for 
1 hour. They were then removed and stored at -70° C in 100 ul aliquots. The heat-inactivated 
preparations o f Schwartz, Johannesburg 25 and D1317 strains, were designated Schwatz-HI 
(Sch-Hl), Johannesburg 25-HI (JHB 25-H1) and D1317-HI respectively (where the suffix HI
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indicates heat inactivated).
2.2 ISOLATION OF PMNLs FROM WHOLE BLOOD
Reagents
Blood units (from SABTS, Johannesburg)
Phosphate Buffered Saline (PBS), pH 7.2 (137 rnM NaCl, 2.7 mM KC1,1.5 mM KH2P 0 4,20mM 
NaH2P 0 4)
Ficoll Hystopaque®-1077 (SigmaDiagnostics Inc., St. Louis, USA)
FCS
Ammonium chloride, pH 7.2 (0 .15M NH4C1, lOmM K H C03, ImM sodiumEDTA)
Trypan blue (0.5% (w/v)]
Units (500ml) of whole anticoagulated (acid citrate dextrose) blood were obtained from the 
South African Blood Transfusion Services (SABTS), Johannesburg. A portion of the blood 
volume was processed and all experiments conducted within 24 hours of blood being taken.
PMNLs were isolated from whole blood using Ficoll-Histopaque®-1077. Two 50 ml falcon tubes 
were used, and 20 ml of blood was added to each tube. An equal volume of PBS was added, and 
mixed with blood in both tubes. A further four 50 ml falcon tubes were used, and 15 ml of Ficoll 
Histopaque was added to each one of them Then, 20 ml of PBS-diluted blood was layered onto 
ficoll hystopaque in each tube. The tubes were centrifuged at 2000 rpm for 30 minutes at room 
temperature. Four layers could be detected after this in the following order from top to bottom 
: plasma, peripheral blood mononuclear cells (PBMCs), ficoll-histopaque and finally PMNLsjust 
above the red blood cells (RBCs). The top three layers were removed and discarded, and the 
PMNL layer (with a small volume of RBCs) was placed in a clean falcon tube. An equal volume 
of PBS was added. Ficoll hystopaque was added to two falcon tubes (15 ml in each tube), and 
20 ml o f the mixture was layered onto this ficoll hystopaque. The tubes were centrifuged at 2000 
rpm for 30 minutes at room temperature. At the end of this, the PMNL layer appeared as a cell 
button above the RBCs. Other layers were discarded and the PMNL layer was transferred to a
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clean tube. Contaminating RBCs were lysed with ammonium chloride until all RBCs were lysed. 
The pellet was washed twice with PBS, following this lysis, and then resuspended in RPM1 1640 
+ 10% FCS. A cell count was determined by trypan blue exclusion dye, a stain which discerns 
live from dead cells. Percentage viability as well as total cell counts were calculated from this, 
and only PMNL preparations with a viability of 95% or more were used in this study.
2.2.1 Inoculation of PMNLs with MV strains
Reagents
VIRAL STOCKS : 
vaccine : Schwartz (Sell) and
heat-inactivated Sell (Sch-HI), 
vaccine-like : Johannesburg 25 (Jhb 25) and 
heat-inactivated Jhb 25 
wild-type : D1317 and
heat-inactivated D1317
PBS
RPMI 1640 
FCS
The concentration of PMNLs was first adjusted to 1 x 107 cells/ml in RPMI. To each of the 7 
clearly marked eppendorf tubes, 1 ml of cell suspension was added. Viral stocks were added to 
the respective tubes and PBS to the control tube (final concentration of 10%), and then mixed 
with the cell suspension by gentle vortexing. The strains mentioned above (under reagents) were 
used to inoculate the PMNLs. PBS was found to give the same results as medium from control 
grown vero cells, and was therefore used throughout this study. Following inoculations, the tubes 
containing inoculated PMNLs were incubated at 37" C (5%) C 0 2) for 1 hour, after which they 
were briefly centrifuged in a micro centrifuge (centrifuge 5415 C), to pellet the cells. The 
supernatant containing unattached virus was gently removed by pipetting, cells washed with PBS 
and the resultant pellet resuspended in 1 ml RPMI 1640 + 10% FCS.
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2.3 ASSAYS OF PMNL FUNCTIONS
2.3.1 Chemolaxis
Reagents
Interleukin-8 (1L-8)
RPMI 1640 + 10% FCS 
anti-CD46 antibody 
Trypan blue
The aim of this test was to measure and compare the migration of PMNLs that have been 
exposed to MV, both live and heat-inactivated, in response to a chemoattractant, 1L-8. PMNLs 
were infected with strains as described 2.2.1. Only RPMI + 10% FCS was added to the control 
wells, while the test wells had IL-8 added to them in addition to RPMI + 10% FCS. Transwell 
inserts (Coming costar, 6.5 mm in diameter, and a pore size of 3 um), were placed in the wells 
of a 24-well plate and allowed to equilibrate for 5 minutes. 100 ul of each cell sample was added 
to each of two wells. The plate was then incubated tor 1 hour at 37° C (5% C 0 2). The inserts 
were removed and the cells in each bottom well thoroughly resuspended with a pipette and 
counted using trypan blue exclusion.
2.3.2 Phagocytosis
Reagents
Phagotest kit® (Orpegen Pharma, Heidelberg, Germany)
Human serum (Bio Whittaker, Maryland, USA)
RPMI 1640
The ability of PMNLs, in the samples mentioned in the preceding sections, to engulf 
microorganisms was measured using a Phagotest kit® (Orpegen Pharma, Heidelberg, Germany),
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with a slight modification to the experimental procedure as detailed in the instruction manual. 
The test kit contains fluorescein (FITC)-labeled opsonized bacteria (E. coli-FITC) and necessary 
reagents to measure phagocytosis and allows for the quantitative determination of leukocyte 
phagocytosis in heparinized whole blood. The experimental procedure was therefore modified 
to allow the quantitative determination of leukocyte phagocytosis in PMNLs isolated from whole 
blood. This assay measures the overall percentage of PMNLs showing phagocytosis (ingestion 
of one or more bacteria per cell) and the capacity of individual cells to phagocytose E. coli 
(number of bacteria per cell or fluorescence intensity).
PMNLs were isolated and infected as described in earlier sections. The PMNLs in all samples 
were then resuspended in RPMI + 50% human serum (instead of FCS). The reason for this step 
was to maximise the opsonization of bacteria by PMNLs. Two tubes were used for each sample 
(i.e. the control and test tube). To the designated tubes, 100 ul of the cell suspension from the 
relevant samples, was added. The tubes were incubated in an ice bath for 10 minutes, to cool 
them down to 0° C. Following the cooling, the E. coli bacteria, which had also been cooled in the 
waterbath, were vortexed and 20 ul added to each tube. The samples were all mixed and the test 
samples incubated at 37° C in a waterbath for 20 minutes, while the control samples remained 
on ice (to prevent phagocytosis). Both the incubation times and temperature were closely 
monitored as these are critical to the success of the assay.
Precisely at the end o f the incubation period all samples together on one rack were 
simultaneously taken out of the water bath and placed on ice in order to stop phagocytosis. To 
each of the tubes, 100 ul of quenching solution was added, and the samples vortexed. The 
contents of each tube were then washed three times for 5 minutes at 1000 rpm at room 
temperature with a washing solution. Two hundred microlitre (200 ul) of a DNA staining 
solution was added to each tube, vortexed, and incubated in an ice bath protected from light for 
20 minutes. A FACSort Flow Cytometer with a 488 nm argon laser (Becton Dickinson, 
California, USA) and Cellquest™ (version 1.0) software, were used to analyse fluorescence, 
within 60 minutes of completion of the assay. The results are expressed as the percentage of 
PMNL within the granulocyte gate that engulf E .coli and as fluorescence intensity or median 
channel shift (determined as median channel number (MCN) obtained for each test sample minus
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the MCN obtained with the negative control tube).
2.3.3 Oxidative Burst 
Reagents
Bursttest™kit (Oipegen Pharma, Heidelberg, Germany)
Human serum (Bio Whittaker, Maryland, USA)
RPMI 1640
The oxidative burst of PMNLs in various samples, was measured in response to E. coli, using 
the Bursttest™ kit (OrpegenPharma, Heidelberg, Germany). This assay allows for the quantitative 
determination of leukocyte oxidative burst in heparinized whole blood. The experimental 
procedure was modified to allow for the quantitative determination of oxidative burst in PMNL 
isolated from whole blood. The kit contains unlabeled opsonized bacteria (E. coli), 
dihydrorhodamine (DHR) 123 as a fluorogenic substrate and necessary reagents. The assay 
determines the percentage of phagocytic cells which produce reactive oxidants (conversion of 
DHR 123 to rhodamine (R 123)) and their enzymatic activity (amount of R 123 per cell or 
fluorescence intensity).
PMNLs were isolated and infected as described in the preceeding sections. As with phagocytosis, 
PMNLs in all samples were resuspended in RPMI + 50% human serum (instead of FCS), to 
maximize opsonization of bacteria. Two tubes (control and test) for each sample were used. To 
each tube, 100 ul of the relevant sample was added, and the tubes were incubated in an ice bath 
for 10 minutes, to cool them down to 0° C. Precooled E. coli bacteria were then mixed well and 
20 ul added to test tubes only. To the control tubes, 20 ul of washing solution was added. All 
samples were mixed, and then incubated in a closed preheated water bath at 37° C for 20 minutes. 
Both the incubation times and temperature were closely monitored. After 20 minutes, all the 
tubes in one rack were put back in an ice bath, and 20 ul of substrate solution was added to each 
tube. The tubes were again incubated for 20 minutes in a water bath, and then washed once with 
3 ml washing solution for 5 minutes at 1000 rpm. The supernatant was discarded and 200 ul
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DNA staining solution was added to each tube. After vortexing, the tubes were incubated in an 
ice bath, protected from light, for 20 minutes, after which the evaluation of oxidative burst was 
done by flow cytometry. The results are expressed as the percentage of PMNL within the 
granulocyte gate that produce reactive oxygen intermediates and as fluorescence intensity or 
median channel shift (determined as median channel number (MCN) obtained for each test 
sample minus the MCN obtained with the negative control tube).
2.3.4 Degranulation
Reagents
0.01 M p-nitrophenyl-P-D-glucuronide 
0.1 M sodium acetate (pH 4)
0.4 M glycine buffer (pH 10)
Cytochalasin B
Triton-XlOO
IL-8
PBS
The aim of this test was to measure and compare the release of a hydrolase, p-glucuronidase from 
azurophilic granules of PMNLs exposed to MV. PMNLs in these samples had been earlier 
incubated for 1 hour at 37° C (5% C 0 2), with the three MV strains, and their heat-inactivated 
preparations, with PBS used as a control. A volume of cells sufficient for the test from each 
sample, was first incubated with Cytochalasin B for 15 minutes at a temperature of 37" C before 
being placed in the respective wells of a round bottom 96-well plate. Four wells were used for 
each sample, and 100 ul of cell suspension was added to each well.
For each sample, the first well was the control well for spontaneous release (PBS), the second 
the test well (IL-8 concentration 500 ng/ml) well, the third as the test well (IL-8 concentration 
62.5 ng/ml) and the fourth one as the control well control for total enzyme release (50% Triton 
X). After the above reagents had been added to these wells, the plate was incubated at 37° C (5%
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CO,) for 30 minutes. The plate was then centrifuged at 1000 rpm for 10 minutes at 4" C. The 
supernatant was collected and transferred to a flat bottom 96-well plate. To this, 100 ul of 0.01 
M p-nitrophenyl-P-D-glucoronide in 0.1 M sodium acetate (pH 4) was added. The plate was left 
overnight at 20° C after which the reaction was stopped with 100 ul of 0.4 M glycine buffer (pH 
10) in each well, and the absorbance was read at 405 nm  The results are expressed as the 
percentage of enzyme released calculated as : [OD405nm in control or test wells/ OD4tl?nm in Triton- 
X100 lysed PMNL (total enzyme)] X 100.
2.4 APOPTOSIS ASSAY
A Cell Death Detection ELISAplus (Boehringer Mannheim, GmbH, Germany) was used to 
quantify histone-associated DNA fragments (mono- and oligonucleosomes) present in the 
cytoplasm of cells undergoing apoptosis.
PMNLs were isolated and infected as described in the preceeding sections, and suspended in 
RPMI + 10% FCS. A round bottom 96-well plate was used, and 200 ul of the cell suspension 
from each of the samples (PBS, Sch, Sch-HI, Jhb 25, Jhb 25-HI, D1317, and D1317-HI), was 
added to the plate. After the plate had been centrifuged at 1000 rpm at room temperature, for 10 
minutes, the medium supernatant was aspirated from each well and discarded. To the remaining 
cell pellet, 200 ul of lysis buffer (provided in the kit) was added, and the plate was left for 30 
minutes at room temperature. The plate was then centrifuged at 1000 rpm for 10 minutes at room 
temperature. From each well, 20 ul of the lysate was transferred into the wells of the EL1SA- 
microtitre plate. The lysates were incubated with 80 ul of an immunoreagent. The plate was 
incubated for 2 hours at room temperature, after which it was washed 3 times with 250 ul of 
incubation buffer in each well. A substrate solution (100 ul), also prepared according to 
instruction in the manual, was added to each well, and the plate was incubated at room 
temperature for 15 minutes. The absorbance was then read at 405 nm  using a plate reader (Organ 
Teknika Reader 230 S (Anthos Labotech Instruments GmbH , Austria).
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2.5 LIGATION OF THE MV RECEPTOR BY ANTI-CD46 ANTIBODY
The aim of this test was to determine whether ligation of the CD46 receptor by an antibody that 
specifically binds this receptor has any effects on PMNL functions already mentioned in the 
preceeding sections. Two PMNL functions, chemotaxis and apoptosis, were chosen for the 
purpose of this investigation. The ability of CD46 antibody to affect IL-8 induced chemotaxis 
and to induce apoptosis were therefore studied.
Instead of inoculating PMNL with MV strains or their heat-inactivated forms, the MV-specific 
receptors, (CD46 receptors), on these cells were ligated by the addition of CD46-specific 
antibody. Two different concentrations of the CD46 antibody and of the isotype control lgG, 
antibody were used. The assays for these PMNL functions were then performed as described in 
sections 2.3.1 and 2.4.
2.6 STATISTICAL ANALYSIS
The SPSS statistical package (SPSS version 10.0 for Windows) was used for the determination 
of statistical significance of results. Comparison of means obtained in various PMNL functional 
assays using uninfected PMNL, PMNL exposed MV strains, their heat-inactivated forms, as well 
as the two antibodies mentioned, was done using a two-tailed T-test. The results were considered 
statistically significant when p < 0.05. All bar graphs show mean values (height of solid bars) 
from multiple determinants and standard errors of the mean (SEM). Line graphs (degranulation 
sections 3.1.4.1 (b) and 3.1.4.2 (b)) show mean values of multiple determinations at two input 
concentrations of IL-8.
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CHAPTER 3
RESULTS
3.1 MV AND PMNL FUNCTIONS
3.1.1 Chemotaxis
3.1.1.1 Exposure of PMNL to MV strains and their ability to migrate in response to IL-8
The ability o f PMNL exposed to the different MV strains to migrate in the absence (random 
migration) and in the presence (direct migration) of a chemoattractant was assessed, using PMNL 
isolated from the blood of 5 healthy individuals.
Random migration of PMNL was not significantly affected by exposure to any of the MV strains 
relative to the uninfected control (/? > 0.05). The response of PMNL to IL-8 was measured as the 
number of cells that migrated across the membrane and were expressed as chemotactic indices 
(that is, the total number of cells that migrated in response to IL-8 divided by the number of cells 
that migrated randomly). The results are depicted in Figure 3.1 on the next page.
The chemotactic index of PMNL exposed to each of the three MV strains, was significantly 
reduced relative to that of the uninfected control (p < 0.05). The reduction in IL-8 induced 
chemotaxis, relative to the uninfected control, occurred to the greatest extent (53%) when PMNL 
were exposed to the wild-type D1317 strain. The decreases observed due to the Schwartz 
(vaccine) and Jhb 25 (vaccine-like) strains were by 45% and 41% relative to the uninfected 
control, respectively (see Fig. 3.1).
The chemotactic index of the Jhb 25-exposed PMNL was 20% higher than that of the D1317- 
exposed PMNL, the only difference, between strains that was significant (p < 0.05).
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Figure 3 .1: Chemotactic index: uninfected PMNL compared to MV-exposed PMNL. Unirtf. C.
= uninfected control; Sch = Schwartz (vaccine strain); Jhb 25 = Johannesburg 
25 (vaccine-like strain) and D1317 = wild-type strain.
3.1.1.2 The effect o f heat-inactivation of M V on the ability of M V-exposed PMNL to 
m igrate in  response to IL-8
AH three MV strains were inactivated by exposure to a temperature o f 56° C for one hour for the 
purpose o f determining how heat inactivation o f the MV strains would affect PMNL migration 
in response to EL-8. The results are shown in Figure 3.2.
Heat inactivation of each of the MV strains, although accompanied by small increases in PMNL 
chemotaxis relative to that o f the untreated MV strains, failed to bring about a significant 
recovery of function to that o f uninfected levels. A comparison o f chemotactic indices o f the 
three MV strains and their heat-inactivated forms showed no significant increases in the 
chemotactic indices (p > 0.05), and all indices were significantly decreased when compared to 
the uninfected control (p < 0.05).
49
Sa
m
pl
e
Uninf. C.
Chemotactic index
8
Figure 3 .2 : Chemotactic indices ofPM NL exposed to both the untreated and the heat-
inactivated forms (HI) o f  the three MV strains used are compared with that o f  the 
uninfected control, Le. PMNL exposed to PBS.
3.1.2 Phagocytosis
The ability ofPMNL exposed to the different MV strains, viz. the Schwartz (vaccine), the Jhb 
25 (vaccine-like) and the D1317 (wild-type) MV strains, to phagocytose bacteria was assessed 
using PMNL isolated from the blood o f 7 healthy individuals. Both the percentage of PMNL 
having ingested fluorescent bacteria and the number o f ingested bacteria per individual cell 
(flourescence intensity or median channel shift), were determined by flow cytometry. The results 
are shown in the bar graphs o f Figures 3.3 and 3.4.
3.1.2.1 PMNL exposure to M V strains and their ability to uhagocvtose bacteria
In all samples in which PMNL were exposed to the three MV strains mentioned above, the
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percentage o f PMNL capable o f undergoing phagocytosis was found to be less than that o f the 
uninfected control (Fig. 3.3A). However, this reduction was only significant in the Schwartz- 
and D1317-exposed PMNL ip  < 0.05), where the percentages o f PMNL having performed
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Figure 3.3 : A. Percentage fluorescent cells (percentage o f  PMNL having phagocytosed 
bacteria). B. Fluorescence intensityfmedian channel shift).
phagocytosis were 22.6% and 19.5% respectively, compared to 34.1% in the uninfected control. 
Effectively, these were reduced by 34% (Schwartz) and 43% (D1317) relative to the uninfected 
control. In the Jhb 25-exposed PMNL, 25% of cells were capable o f phagocytosis, but the 
reduction in phagocytosis was not significant when compared to the uninfected control (p > 
0 05)
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MV-exposed PMNL also showed a reduction in the number of ingested bacteria per individual 
cell (measured as median channel shifts) when compared to the uninfected control (Fig. 3.3B). 
A decrease of more than 50% in the median channel shift in each of the three MV-exposed 
PMNL was observed, with the D 1317-exposed PMNL showing the greatest reduction (71 %). The 
reductions with the other two strains were 58% (Schwartz) and 54% (Jhb 25). See Fig. 3.3B.
Comparison of the median channel shifts of the MV-exposed PMNL, revealed the same trends 
as in for percentage of fluorescent cells. The highest median channel shift was observed in the 
Jhb 25-exposed PMNL. The medium channel shift measured in the Schwartz-exposed PMNL 
was slightly lower than that of the Jhb 25-exposed PMNL (p > 0.05), and 47% higher than that 
of the D1317-exposed PMNL (p < 0.05). Comparison of the median channel shift in the Jhb 25- 
exposed PMNL with that of the D 1317-exposed PMNL, showed a 38% reduction in the median 
channel shift of the D 1317-exposed PMNL relative to the Jhb 25-exposed PMNL. This reduction 
was significant (p <0.05). The results are shown in Fig. 3.3B.
3.1.2.2 The effect of heat inactivation of MV on the ability of MV-exposed PMNL to 
phagocvtose bacteria
All three MV strains were inactivated by exposure to a temperature of 56° C for 1 hour, following 
which PMNL were exposed to each strain for 1 hour, and phagocytosis then measured.
Exposure of PMNL to heat-inactivated forms of all three MV strains, was accompanied by small 
increases in the percentage of PMNL that performed phagocytosis. These increases were, 
however, not enough to restore the percentage of fluorescent cells to that found for the uninfected 
control (Fig. 3.4A). The Schwartz-HI-exposed PMNL showed an increase of 23% relative to its 
untreated form (p < 0.05), while the apparent increase in the Jhb 25-Hl-exposed PMNL relative 
to its untreated form was not significant (p > 0.05). The increase was greater by 43% in the 
D1317-HI-exposed PMNL when compared to its untreated form (p < 0.05). See Fig. 3.4A.
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Figure 3.4 : Phagocytosis results for PMNL exposed to MV and Hl-MV strains, as well as the 
uninfected control, are shown. A. Percentage fluorescent cells. B. Fluorescence 
intensity (median channel shift).
Heat inactivation of MV was accompanied by an increase in the number of ingested bacteria per 
individual cell as seen by increases in fluorescence intensity (median channel shift) of all PMNL 
exposed to heat-inactivated forms o f the three MV strains (Fig. 3.4B). However, this still fell 
short o f restoring phagocytosis to the level of the uninfected control (p < 0.05). The reversal 
occurred to the greatest extent in the D1317-HI-exposed PMNL, which was almost 3 times 
higher than its untreated form (D1317) (p < 0.05). The heat-inactivated forms o f Jhb 25 (Jhb 25- 
HI) and Schwartz (Schwartz-HI) showed increases of 45% and 53% respectively in median 
channel shift when compared to their untreated forms (p > 0.05).
53
3.1.3 Oxidative burst
The effect of MV on PMNL oxidative burst was quantitatively determined using the Bursttest 
kit. PMNL were isolated from whole blood obtained from 8 healthy individuals. The percentage 
o f cells having produced reactive oxygen intermediates (ROI) and their fluorescence intensity 
(median channel shift), were analysed by flow cytometry.
3.1.3.1 PMNL exposure to MV strains and their ability to produce reactive oxygen 
intermediates
The percentage of PMNL that produced reactive oxygen radicals when induced by E. coli was 
less in all MV-exposed samples when compared to the uninfected control (Fig. 3.5 A). The 
reduction occurred to the greatest extent in the D1317-exposed PMNL which showed a decrease 
of 41% in the percentage of cells having produced reactive oxygen radicals, relative to the 
uninfected control (p  < 0.05). Both the Schwartz- and the Jhb 25-exposed PMNL showed a 
reduction of 35% in the percentage of cells having produced reactive oxygen radicals (p < 0.05) 
(see Fig. 3.5 A). There were no significant differences between the different MV strains in their 
ability to reduce ROI production. Analysis of the fluorescence intensity as determined by the 
median channel shifts showed the same trends to that found for proportions of fluorescing cells 
(Fig. 3.5 B), but with all reductions due to exposure to MV found not to be statistically 
significant (p  > 0.05). Inter-strain comparison of median channel shifts of the three MV-exposed 
PMNL samples revealed no significant differences (p > 0.05).
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Figure 3.5 : Oxidative burst results for uninfected PMNL and those of PMNL exposed to MV 
strains. A. Percentage of cells producing ROI. B. Fluorescence intensity 
(median channel shift).
3.1.3.2 The effect o f heat inactivation o f M V on the ability of M V-exposed PMNL to 
produce R O I
As with phagocytosis, a reversal o f the trends was observed in PMNL exposed to the heat- 
inactivated forms o f the three MV strains. These reversals were apparent mainly in the median 
channel shift measurements and not in the proportions o f PMNL capable o f producing reactive 
oxygen radicals (see Figs. 3.6 A and 3.6 B).
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The median channel shift (fluorescence intensity) observed in PMNL exposed to the above MV 
heat-inactivated strains, tended to be increased relative to those exposed to MV strains not heat- 
inactivated. The Schwartz-HI-exposed cells showed an increase o f 38%, the Jhb 25-HI-exposed 
PMNL an increase o f 31% and D1317-HI-exposed PMNL increase o f 15% in the median channel 
shift compared to their respective untreated forms. Once again, the differences in the number of 
cells having produced reactive oxygen intermediates, as well as the median channel shifts 
between the three heat-inactivated MV-exposed PMNL were very small and statistically 
insignificant (p > 0.05).
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Figure 3.6 : Oxidative burst results for PMNL exposed to both the MV and HI-MV strains, 
and the uninfected control A. Percentage o f PMNL having produced ROI. B. 
Fluorescence intensity (median channel shift).
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3.1.4 I)tM»raniilatinn
The ability of PMNL exposed to the three MV strains, as well as their heat-inactivated forms, to 
undergo degranulation in the absence and in the presence o f IL-8, was assessed using blood 
obtained from 7 healthy individuals. The results are shown Figs. 3.7, 3.8, 3.9, 3.10, 3.11 and 
3.12.
3.1.4.1 PMNL exposure to M V strains and the induction o f degrannlatinn 
(a) MV induction o f the release o f B-ghicnronidase from PMNL
Before determining if MV could alter degranulation in response to a potent chemokine such as 
IL-8, it was important to determine if MV alone had the ability to directly affect degranulation 
of PMNL. PMNL exposed to the different MV strains, showed no differences in the percentage 
o f P-glucuronidase enzyme released from cells when compared to that released by uninfected 
control PMNL (Fig. 3.7) (p > 0.05). Therefore the different MV strains did not have the ability 
to directly induce degranulation o f PMNL.
100-.
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Figure 3.7 : Degranulation : Spontaneous and MV-induced /3-glucuronidase release.
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(b) Interleukin-8 (IL-8) induced release of ft-glucuronidase enzyme
It was next questioned whether MV had the ability to alter degranulation in response to a potent 
agonist, IL-8.Overall, p-glucuronidase release observed in all samples was higher, as would be 
expected, than that observed in the same samples exposed to a lower IL-8 concentration. 
Although the MV-exposed PMNL, with the exception of the D1317-exposed PMNL showed a 
higher percentage enzyme release relative to the uninfected control, inter-strain comparisons 
showed small and insignificant differences in percentage enzyme release (p > 0.05). Therefore, 
in addition to not directly affecting degranulation, MV strains also had no effect on the ability 
of IL-8 to adequately induce degranulation.
Uninf. C . ------------Sch.
Jhb 25 ------------  D1317
Figure 3.8 : Percentage enzyme release in the uninfected control and MV-exposed PMNL at a 
low and high IL-8 concentration.
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3.1.4.2 FMNL exposure to heat-inactivated MV strains and the induction of degranulation
(a) Induction o f degrannlation bv heat-inactivated MV strains
Although, on the basis o f the aforementioned findings it would seem unlikely that heat 
inactivation o f the MV strains would have any effect, the HI forms were nonetheless tested. In 
the absence of EL-8, the percentage enzyme release induced by the heat-inactivated forms o f each 
of the three MV strains was in some instances raised compared to the corresponding untreated 
form. However, these increases were very small and all statistically insignificant (p > 0.05). See 
Fig. 3.9.
Q.
Ea
(/}
D1317-HI 
D1317 
Jhb 25-HI 
Jhb 25 
Sch-HI 
Sch 
Uninf. C.
0 10 20 30 40
%  p -glucuronidase release
50
Figure 3.9 : Comparison of percentage enzyme release between the uninfected control, MV- 
and Hl-MV-exposed PMNL.
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(b) IL-8 induced release of B-glucuronidase
(i) Schwartz and Schwartz-HI
-------------  S ch  ------------- Sch-HI
Figure 3.10 : Comparison o f percentage glucuronidase release by PMNL exposed to the 
Schwartz and Schwartz-HI MV strains.
(ii) Jhb 25 and Thb 25-HI
Jhb 25 ------------Jhb 25-HI
Figure 3.11: Comparison o f percentage ff-glucuronidase release by PMNL exposed to the Jhb 
25 and Jhb 25-HI MV strains.
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(iii) D1317 and D1317-HI
-------------  D1317 ------------- D1317-HI
Figure 3.12 : Comparison o f percentage fi-glucuronidase release by PMNL exposed to 
the D1317 and D1317-H1 MV strains.
All HI forms of MV showed no significant effects on degranulation in response to IL-8 (tested 
at concentrations 62.5 and 500ng/ml) in relation to their non-HI counterparts (p > 0.05).
3.2 MV AND INDUCTION OF APOPTOSIS
A Cell Death Detection EL1SAPIUS kit was used to quantify histone-associated DNA fragments 
(mono- and oligonucleosomes) present in the cytoplasm of cells undergoing apoptosis. The 
ability of MV strains to directly induce apoptosis in PMNL was determined by first exposing 
PMNL from 6 healthy blood donors to each of the strains for 1 hour and then measuring the 
extent of apoptosis.
3.2.1 Exposure of PMNL to different MV strains and the induction of apoptosis
Apoptosis was induced in PMNL by all three MV strains (p < 0.05). As depicted in Fig. 3.13, this
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occurred to the greatest extent (90%) with the wild-type D 1317 strain, which in turn was greater 
than that induced by both vaccine (28%), and vaccine-like strains (54%) (p < 0.05). Although 
there was a trend towards increased apoptosis when PMNL were exposed to the Jhb 25 strain as 
opposed to the Schwartz strain, this was not found to be significant (p > 0.05).
Sample
Figure 3.13 : Apoptosis measured in PMNL exposed to the three MV strains, the negative 
control (Neg. Con.), uninfected control (Uninf. C.), as well as the positive 
control (Pos. Con).
D1317-exposed PMNL showed an increase o f 49% (p < 0.05) and 24% (p < 0.05) when 
compared to the Schwartz- and Jhb 25- exposed PMNL, respectively (Fig. 3.13). Apoptosis was 
also observed in the uninfected controls, the reason for that being that PMNL are terminally 
differentiated cells, and once isolated from whole blood they begin to undergo apoptosis at a 
slow rate.
3.2.2 Heat inactivation o f M V strains and induction o f apoptosis
Heat inactivation of MV strains only significantly reduced apoptosis induced by the wild-type 
strain D1317 by 29%, this still being 35% above that of the uninfected control (p < 0.05) (see
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Fig. 3.14). Heat inactivation o f MV, however, had no significant effect on apoptosis induced by 
either the Schwartz (vaccine) strain or the Jhb 25 (vaccine-like) strains (p > 0.05V
0)
a
E(0
(/)
D1317-HI 
D1317 
Jhb 25-HI 
Jhb 25 
Sch-HI 
Sch 
Pos. Con 
Uninf. Con. 
Neg. Con.
0.00 0.25 0.50 0.75 1.00 1.25 1.50 1.75 2.00
Optical density (405 nm)
Figure 3.14 : Apoptosis in PMNL exposed to MV and HI-MV strains, uninfected control, 
negative control, and positive control.
3.3 LIGATION OF THE M V RECEPTOR BY ANTI-CD46 ANTIBODY
CD46 functions as the cellular receptor for MV. As MV is not known to productively infect 
PMNL, and exposure of PMNL to MV in the above experiments was only for 1 hour, defects in 
various PMNL functions described are likely to be due to an early event in the MV-cell 
interaction. In order to establish if the binding o f MV to the receptor could be the event leading 
to the reduction in the various PMNL functions described, it was questioned whether ligation of 
the CD46 receptor by an antibody that specifically binds this receptor, could in a similar way 
reduce specific PMNL functions. The ability o f CD46 antibody to affect 1L-8 induced chemotaxis 
and to induce apoptosis was therefore studied. The results are shown in Figs. 3.15 and 3.16.
63
3.3.1 Chemntaxis
Chemotaxis was inhibited by CD46 antibody in a dose-dependent manner. A reduction o f 5% 
in the chemotactic index was found when a tow concentration of anti-CD46 (5 ug/ml) was added 
to cells. The reduction was more pronounced in those PMNL exposed to a higher antibody 
concentration (25 ug/ml), and was 24% less than that recorded in PMNL exposed to a low CD46 
antibody concentration (p < 0.05). These reductions from normal in chemotactic indices due to 
both the low and high antibody concentrations were significant (p < 0.05).
Exposure of PMNL to different concentrations o f the control isotype, IgGt, was accompanied by 
an increase in the chemo tactic index relative to the uninfected control For PMNL exposed to a 
low concentration o f IgG! (5 ug/ml), an increase o f 11% in chemo tactic index, relative to the 
uninfected control was observed (Fig. 3.15). In those PMNL exposed to a higher IgGj 
concentration (25 ug/ml), the increase in chemotactic index was 32% higher than that recorded
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Figure 3.15 : Chemotactic indices o f untreated PMNL (control) and those o f PMNL exposed to 
both the high and low concentrations of the CD46 and IgGt antibodies.
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for the uninfected control. Both increases were significant (p < 0.05). The chemotactic index 
recorded for those PMNL exposed to a higher IgG, antibody, was significantly raised relative to 
that recorded in those PMNL exposed to a lower concentration (p < 0.05). Therefore an increase 
in the concentration of the control isotype antibody, IgG,, was accompanied by an increase in the 
chemotactic index.
In summary, exposure to the CD46 antibody led to an inhibition of chemotaxis as seen by the 
reduction of in the chemotactic index with an increase in dose. On the other hand, exposure of 
PMNL to the isotype control IgG! antibody had an enhancing effect on chemotaxis of PMNL as 
shown by an increase in the chemotactic index as the dose was increased. These latter findings 
strongly suggest that the effects on chemotaxis of the CD46 antibody binding to PMNL are not 
in anyway due to non-specific binding of the CD46 antibody to the Fc receptors. Furthermore, 
binding of Fc receptors by IgG, molecules in their own right elicit effects quite opposite to that 
of the CD46 antibody on chemotaxis.
3.3.2 Apoptosis
After exposure of PMNL to two concentrations o f the anti-CD46 antibody (5 ug/ml and 25 
ug/ml) and two concentrations of the isotype control antibody, IgG,, (5 ug/ml and 25 ug/ml), for 
a period of 1 hour, apoptosis was determined by measuring the optical densities of the samples 
in the apoptosis assay (ELISA). This measurement was carried out in order to determine whether 
occupation of the CD46 receptors by these antibodies would have any effect on apoptosis.
Exposure of PMNL to both concentrations of the CD46 antibody, was accompanied by an 
increase in optical density relative to the uninfected control (p < 0.05). The greatest increase in 
apoptosis was recorded in those PMNL exposed to the high CD46 antibody concentration (25 
ug/ml). An increase of 220% relative to the uninfected control was observed. At the low CD46 
antibody concentration of 5 ug/ml, the optical density observed was lower than that recorded at 
the high antibody concentration, but was nearly twice that of the uninfected control. The 
difference in optical density between PMNL exposed to 5 ug/ml and 25 ug/ml of the CD46 
antibody, was significant (p = 0.05).
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Control *9G1 (5 u9/ml) '9 ^  (25 ug/ml) CD46 (5 ug/m|) c d 46 (25 ug/ml)
Sample
Figure 3.16 : Optical densities from  PMNL samples exposed to the two concentrations o f the 
CD46 and IgGj antibodies are compared to that o f  untreated PMNL (control).
The trend was similar for IgG, antibody-exposed PMNL to that observed for the anti-CD46- 
exposed PMNL. PMNL exposure to the isotype control antibody, IgG,, resulted in an increase 
in apoptosis, as seen by increases in the optical densities o f samples exposed to the two 
concentrations o f this antibody (Fig. 3.16). The optical density recorded in PMNL exposed to a 
low IgG, concentration (5 ug/ml) was 75% higher than that recorded in the uninfected control 
(p < 0.05). As the concentration o f the IgG! antibody was raised from 5 ug/ml to 25 ug/ml, the 
optical density dropped, but still remained elevated (63% higher) compared to the uninfected 
control (p < 0.05). Therefore, apoptosis was induced to some extent by exposure to IgG, antibody 
but not to the extent o f that induced by anti-CD46 antibody.
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CHAPTER 4
DISCUSSION
4.1 MV AND PMNL FUNCTIONS
4.1.1 Chemotaxis
Chemotaxis, a process of directed movement of cells along a gradient of increasing concentration 
of the attracting molecule (referred to as a chemoattractant), is a property that cells of the 
immune system use to migrate to the site of infection where the concentration of chemotactic 
factors is highest (i.e. the epicentre of the inflammatory process). PMNL are the first cells of the 
immune system to migrate to the site of microbial invasion, and are the principal cells involved 
in the immune response to invasion of the host by microbes, particularly bacteria and fungi.
Exposure of PMNL to all three MV strains used in this study, viz Schwartz (vaccine strain), 
Jhb 25 (vaccine-like strain) and D1317 (wild-type strain), resulted in significant reductions in 
PMNL chemotaxis in response to a chemoattractant, IL-8. The wild-type strain D 1317 had the 
greatest impact in this regard. However, when compared to other strains, it was found to he 
significantly different only to the Jhb 25 exposed PMNL.
A slight recovery of function was observed when PMNL were exposed to MV strains which had 
been inactivated by heating at 56° C for 1 hour. This recovery failed to bring about complete 
restoration of the chemotactic function of PMNL, and as such, the chemotactic indices remained 
significantly reduced when compared to the uninfected control. Clearly, the movement of PMNL 
in response to a chemoattractant, IL-8, was reduced by exposure of these cells to both the MV 
and heat-inactivated MV strains.
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4.1.2 Phagocytosis
A key component of any host defence system is the ability to ingest and destroy offending 
microorganisms. In the phagocytic process, PMNL are capable of ingesting more than one 
microorganism at once. In situations where large numbers of PMNL are involved in this process, 
an abscess filled with pus (dead or dying PMNL) may form
The phagocytic ability of PMNL was clearly compromised by exposure of these cells to all MV 
strains. Both the proportion of cells phagocytosing bacteria (E. coli), and the number of bacteria 
within the cells were significantly reduced. As with chemotaxis, the wild-type MV strain, D1317 
had the greatest impact on the phagocytic function of PMNL where both the proportion of cells 
performing phagocytosis, defined as percentage fluorescent cells, and the number of bacteria 
ingested by each PMNL, defined as the median channel shift, were the lowest recorded. The fact 
that the number of bacteria phagocytosed by PMNL exposed to the wild-type strain D 1317 were 
reduced by 71% when compared to those ingested by PMNL in the uninfected control, is 
testimony to the fact that the wild-type strain D1317 was the most potent inhibitor of 
phagocytosis, of the three MV strains used. It was also interesting to note that PMNL exposed 
to all MV strains were only capable of phagocytosing less than half the number of bacteria that 
PMNL in the uninfected control could ingest.
Virus inactivation, through heating, brought about some improvement in PMNL phagocytic 
ability. Both the percentage of cells ingesting bacteria and the number of bacteria ingested in 
each cell rose when PMNL were exposed to heat-inactivated MV strains. As in the case of 
untreated MV strains, the trend observed with PMNL exposed to heat-inactivated MV strains was 
the same in both the percentage of cells phagocytosing bacteria and the fluorescence intensity. 
As with chemotaxis, recovery of function was observed in PMNL exposed to heat-inactivated 
MV strains, but complete restoration of function was not achieved. Both the percentage of PMNL 
ingesting bacteria and the number of phagocytosed bacteria within PMNL exposed to heat- 
inactivated MV strains, remained significantly reduced relative to the uninfected control.
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4.1.3 Oxidative burst
This is a mechanism through which phagocytosed microorganisms can be killed. It is an oxygen- 
dependent mechanism and is also called the respiratory burst. It involves the production of 
reactive oxygen intermediates which are highly toxic to ingested microorganisms.
As with chemotaxis and phagocytosis, this PMNL function was negatively affected by exposure 
o f PMNL to the three MV and the three heat-inactivated MV strains. Significant reductions in 
both the percentage of cells producing reactive oxygen intermediates (ROI), measured as the 
percentage of fluorescent cells, and their fluorescence intensity, measured as the median channel 
shift were observed. The trends were the same for both the percentage of fluorescent cells and 
the median channel shifts. While oxidative burst was significantly reduced in PMNL exposed 
to all three MV strains relative to the uninfected control, an inter-strain comparison of percentage 
fluorescent cells and median channel shift of PMNL exposed to all three MV strains revealed no 
significant differences.
Heat inactivation of MV strains and subsequent exposure of PMNL to these strains had a 
negligible impact on the percentage of fluorescent cells and fluorescence intensity. As observed 
for PMNL functions of chemotaxis and phagocytosis, exposure of PMNL to heat-inactivated MV 
strains, although accompanied by an improvement in oxidative burst, failed to bring about 
complete restoration of the oxidative burst function of PMNL not exposed to MV.
4.1.4 Depranulation
This is the other of the two mechanisms by which phagocytosed microbes can be killed, and 
unlike oxidative burst is an oxygen-independent mechanism It involves the release of 
microbicidal enzymes such as lysozyme and cathepsins into an intracellular vacuole, the 
phagosome, and the digestion of the ingested microbe by these enzymes.
Percentage enzyme release, in the absence of IL-8, in PMNL exposed to all three MV, was 
similar to that observed for uninfected PMNL. Inter-strain comparisons and comparisons with
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the uninfected control in IL-8 induced degranulation assays revealed no differences. 
Degranulation in all PMNL preparations (untreated and MV-infected) was raised when measured 
in the presence of a high IL-8 concentration (500 ng/rnl), as compared to a low IL-8 
concentration. MV therefore did not alter the expected dose-dependent effects of IL-8 on PMNL 
degranulation.
While PMNL functions of chemotaxis, phagocytosis and oxidative burst were severely 
compromised by exposure of these cells to MV and heat-inactivated MV strains, the PMNL 
function of degranulation appears not to have been affected by exposure to the MV strains.
4.2 MV AND INDUCTION OF APOPTOSIS
Apoptosis, also called programmed cell death, is a genetically controlled pre-programmed event, 
through which unwanted cells are eliminated during development. Several microorganisms are 
known to induce apoptosis.
In this study, it was found that all three MV strains considered, significantly induced apoptosis 
in PMNL. Of the three MV strains, the wild-type strain, D 1317, was the most potent inducer of 
apoptosis in PMNL. Apoptosis due to this strain was significantly raised when compared to that 
in the uninfected control, the Schwartz- and the Jhb 25-exposed PMNL. No significant difference 
in apoptosis was observed when the Schwartz-exposed PMNL were compared to the Jhb 25- 
exposed PMNL.
Heat-inactivation of MV strains did not have any appreciable effect on apoptosis induced by any 
of the strains, relative to the uninfected control. Apoptosis in PMNL exposed to heat-inactivated 
forms of all three MV strains, though slightly reduced relative to their untreated forms, were still 
high when compared to that of the uninfected control. The only significant reduction in apoptosis 
was observed when the D 1317-expo sed PMNL were compared to the D 1317-HI-exposed PMNL. 
Therefore, in addition to effects of MV on different PMNL functions, MV also had the ability 
to directly induce apoptosis of these cells.
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4.3 LIGATION OF THE MV RECEPTOR BY ANTI-CD46
ANTIBODY
The membrane co-factor CD46 functions as a receptor for MV. This receptor was ligated by anti- 
CD46 antibody (an antibody that specifically binds this receptor) for the purpose of establishing 
whether binding of MV to this receptor could be the event leading to the suppression of PMNL 
functions described. The ability of CD46 antibody, through binding to the CD46 receptor, to 
affect IL-8-induced chemotaxis and to induce apoptosis of PMNL was therefore chosen for study.
4.3.1 Chemotaxis
PMNL exposure to the CD46 antibody was accompanied by a reduction in chemotaxis. This 
reduction occurred in a dose-dependent manner, i.e. a lower chemotactic index was observed in 
PMNL exposed to the higher CD46 antibody concentration. The implication here is that as the 
CD46 antibody concentration is raised, this leads to an increased occupation of the CD46 
receptors on PMNL by this antibody, and this negatively affects PMNL chemotaxis as seen by 
the reduction in the chemotactic index.
Interestingly, the opposite results were observed when PMNL were exposed to the two 
concentrations of the isotype control antibody, IgG,. This antibody was included to ensure that 
CD46 antibody effects were specific and not due to non-specific binding of antibody. Even at a 
low IgG, antibody concentration, the chemotactic index of PMNL exposed to this antibody was 
elevated when compared to that in the uninfected control. As the isotype control antibody 
concentration was raised, the chemotactic index increased. Therefore, this antibody rather than 
having no effect appeared to enhance IL-8 induced chemotaxis. These results are suggestive of 
a role for ligation of Fc receptors (by anti IgG, antibody) of PMNL in chemotaxis induced by 
1L-8. PMNL are known to have large numbers of Fc receptors on their membranes (Abramson 
and Wheeler, 1994).
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4.3.2 Apoptosis
Exposure of PMNL to the CD46 antibody significantly increased apoptosis in these cells with 
increasing anti-CD46 concentration. The trend observed was the opposite of that observed with 
chemotaxis where the reduction occurred in dose-dependent manner. It was also noted that at a 
low CD46 antibody concentration, apoptosis was still significantly elevated relative to the 
uninfected control.
At a low isotype control IgG, concentration, PMNL apoptosis was significantly increased. 
Raising the concentration of the isotype control antibody was accompanied by a reduction in 
apoptosis. As seen with chemotaxis, this antibody by binding Fc receptors also affects PMNL 
apoptosis. The trend observed in the IgG! antibody-exposed PMNL was the opposite of that 
noticed in the CD46 antibody-exposed PMNL. While increasing the IgG] antibody concentration 
led to a decrease in apoptosis (although both still significantly increased relative to the control), 
increasing the CD46 antibody concentration was accompanied by an increase in apoptosis.
The effects of anti-CD46 antibody, by specifically binding CD46, appear to mimic those of the 
different MV strains on both PMNL chemotaxis and apoptosis, suggesting that these effects are 
mediated at the level of virus binding to CD46 on PMNL. These results would further suggest 
that increased occupation of MV receptors on PMNL by increased doses of MV would likely 
exacerbate the negative effects on the cell functions studied, as well as increase the rate of 
apoptosis.
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CHAPTER 5
CONCLUSION
The role of PMNL in controlling infection by viruses within the host is often minimal compared 
to that of mononuclear cells. However, PMNL are the principal cells involved in the immune 
response to invasion of the host by bacteria and fungi. They provide the first line of defence 
against invasion of humans by bacterial and fungal microorganisms. Therefore any virus-induced 
PMNL dysfunction, resulting in alteration of any of the PMNL functions mentioned in the 
preceeding chapters (chemotaxis, phagocytosis, degranulation and oxidative burst) could result 
in a situation were there is decreased movement of PMNL to the site of microbial infection, and 
lead to depressed bactericidal activity against invading organisms (Abramson and Mills, 1988).
Several viruses have been implicated in the depression of one or more of these PMNL functions. 
In addition to quantitative defects in PMNL function induced by viruses, qualitative deficiencies 
of PMNL can also occur in patients with viral infections. In patients who experience a decrease 
in the number of peripheral blood PMNL to less than 1 000 cells/mm3, there is an inverse 
correlation between the absolute number of circulating PMNL and the incidence o f bacterial and 
fungal infections. Patients with qualitative or quantitative PMNL abnormalities are prone to 
similar infectious complications - recurrent tissue infections due to bacterial or fungal agents that 
invade from skin or mucous membranes. In both groups of patients, organisms such as 
Staphylococcus aureus, enteric species, and candidal species are among the commonest. While 
localized infections in neutropenic patients commonly progress to life-threatening or irreversible 
septicaemia, established infections in patients with disorders of leukocyte function generally are 
limited or contained within superficial tissues or the reticuloendothelial system (Abramson and 
Mills, 1988).
Quantitative defects such as neutropenia are common in HIV-1 infected individuals (Jacobson 
et a l, 1997). Other studies conducted report functional defects in PMNL from HIV-1-infected 
patients, and include defects in phagocytosis (Lazzarin et al., 1986; Shalekoff et a l, 1998),
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chemotaxis (Valone et a l, 1984; Ellis et a l, 1988; Meddows-Taylor et a l, 1998), bacterial 
killing (Ellis et a l, 1988; Murphy et al., 1988), oxidative burst (Chen et a l, 1993; Pitrak et al., 
1993; Shalekoff et al., 1998) and degranulation (Meddows-Taylor et al., 1999).
While the role of viruses such as Influenza, Parainfluenza, Cytomegalovirus, Herpes simplex, 
Varicella zoster, Hepatitis B, HIV and Respiratory syncytial vims, in the suppression of PMNL 
functions, and the impact that this suppression has on predisposition to secondary microbial 
infections, have been thoroughly studied, the same is not true for MV. The only study in this 
regard has been conducted by the Anderson group (Anderson, et al., 1976), who reported 
depressed PMNL chemotactic activity in children with MV infection. How MV infection results 
in suppressed PMNL function, directly through interaction of vims and the host cell, or indirectly 
through MV-induced immune processes, is not known.
This study, therefore, set out to determine whether MV had any suppressive effect on a number 
of PMNL functions. The direct effect of MV on chemotaxis, phagocytosis, oxidative burst, 
degranulation and on apoptosis of PMNL was therefore studied. This study reports, for the first 
time, that direct exposure of PMNL to MV strains, whether wild-type or vaccine, heat-inactivated 
or not, had an inhibitory effect on several PMNL functions. The PMNL function of degranulation 
was not affected by exposure to MV strains and their heat-inactivated forms. This study has 
further revealed that exposure of PMNL to all MV strains used resulted in an increase in the rate 
at which the cells underwent programmed cell death (apoptosis).
Overall, the wild-type strain, D1317, had the greatest suppressive effect on PMNL function of 
the three strains tested. Wild-type MV strains have been found to be more virulent than vaccine 
strains (Lorenz and Albrecht, 1980). MV replication following acute infection is accompanied 
by the production of large amounts of vims. This will most likely have a greater impact on 
PMNL function in vivo. In general, the level of suppression of PMNL functions was less in the 
vaccine (Schwartz)-exposed PMNL when compared to the vaccine-like (Jhb 25)-exposed and 
the wild-type (D1317)-exposed PMNL. It is believed that attenuation of virulence is associated 
with decreased vims replication in lymphatic tissue (Ono et al., 1970), diminished viraemia (von 
Binnendijk et a l,  1994) and failure to induce pathologic changes in neural tissue (Buynak et a l,
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1962). It can be seen in this study that even though direct effects due to vaccine strains are 
evident, because of reduced viral replication due to virus attenuation, the low amount of virus 
produced is more likely to have less of an effect on PMNL. From the results of this study it is 
clear that attenuation o f MV strains could to a small extent abrogate the PMNL suppression 
observed with wild-type virus.
The question of virus inactivation, was investigated by subjecting all three MV strains to a 
temperature of 56° C for 1 hour, prior to exposing PMNL. There were slight improvements in 
PMNL functions relative to non-HI virus, though not adequate (i.e. PMNL functions never 
improved to the level observed in the uninfected control). Heat-inactivation certainly brought 
about a slight abrogation or suppression, although this was not enough to completely restore 
normal function. This suggests that the process of heating could be affecting some protein or 
protein activity (perhaps enzymatic) involved in MV binding and/or internalization. It may be 
significant that heat inactivation of the wild type virus significantly decreased apoptosis in wild 
type MV-exposed PMNL, suggesting that wild type virus may in fact have a more potent enzyme 
activity that is affected by heat than the more attenuated strains.
In addition to the qualitative defects in PMNL functions observed in this study, the issue of 
quantitative defects in PMNL should also be considered. MV could be capable of reducing the 
number of circulating PMNL in vivo by inducing apoptosis (i.e. accelerating the rate at which 
these cells are ‘committing suicide’), directly through virus binding to CD46 receptors or 
indirectly through MV-induced immune processes. Suppression of the above functions and 
reductions of PMNL in the MV-infected host could be the result of increased apoptosis of these 
cells. It is a known fact that cells of multinuclear organisms are capable of self-destruction in 
response to a wide variety of stimuli, by simply activating an intrinsic cell suicide programme 
within them. This normally happens when these cells are no longer needed or have become 
seriously damaged, either through radiation or viral infection, among others. This process called 
apoptosis, is a genetically preprogrammed event which occurs in a controlled manner to eliminate 
unwanted cells during the course of normal development (Teodoro and Branton, 1977). A variety 
of stimuli, physiological and non-physiological, among them metabolic disturbances due to 
chemical insults, virus infections or aberrant growth induced by the activation of oncogenes, can
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provoke or accelerate this process (vaux and Strasser, 1996). If this happens, an imbalance can 
he created between the number of cells produced and those eliminated, i.e. more cells will be 
destroyed than can be replaced at any one time. As a result a decrease in circulating PMNL can 
occur, and this can also predispose the host to bacterial and fungal infections.
Apoptosis was significantly raised in all PMNL samples directly exposed to MV strains. The 
highest apoptotic rate was recorded in the D1317 (wild-type) -exposed PMNL samples. This 
accelerated PMNL destruction due to virus exposure could have severe consequences for the 
MV-infected host as this could affect the ability of PMNL to respond appropriately to invading 
bacteria or fungi, these cells being compromised in terms of function (chemotaxis, phagocytosis, 
oxidative burst) and perhaps in terms of circulating cell numbers.
Having observed all these defects due to MV, the mechanism involved in this suppression was 
questioned. As MV is not known to productively infect PMNL, and exposure of PMNL to MV 
in all the experiments conducted was only for 1 hour, the defects observed in the PMNL 
functions described are likely due to an early event in the MV-cell interaction. In order to 
establish if the binding of MV to the receptor could be the event leading to the suppression 
observed in PMNL functions, it was questioned whether ligation of the MV-specific receptor, 
CD46, by an antibody that specifically binds this receptor, could in a similar way affect PMNL 
functions.
As mentioned earlier, the transmembrane protein CD46 is a receptor for MV. It is a member of 
the cluster of genes that regulate complement activation and protects cells from autologous 
complement-mediated damage (Liszewski, et al., 1991). CD46 can occur in as many as 14 
different isoforms because of alternative splicing of its mRNA (Russel, et al., 1992). All 
isoforms share, at the N-terminus, a fourfold repeat of the short consensus repeat (SCR) region, 
a characteristic feature o f the regulators of complement activation located close to the plasma 
membrane and the first part o f the transmembrane domain. The isoforms differ in their use of 
three exons encoding three STP (Ser, Thr, and Pro)- rich regions (called A, B and C) and in three 
exons encoding the second part of the transmembrane region and the cytoplasmic tail (the two 
major ones are called CYT 1 and CYT 2). The expression of the various CD46 isoforms varies
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from one tissue to another and may potentially govern tissue sensitivity to MV infection (Russel, 
et al., 1992).
Binding of MV is the primary function of CD46 as a virus receptor (Varior-Krishnan, et al., 
1994). The envelope glycoprotein haemagglutinin (H) of MV is the ligand of CD46 (Gerlier, et 
al., 1994). This interaction leads to a specific downregulation of CD46 by internalization. The 
H-mediated CD46 downregulation is reversible and restricted to CD46 since expression of other 
four surface markers (CD3, CD 14, CD47 and CD63) is unaffected (Krantic, et al., 1995). After 
binding to its target cell, MV has to fuse with the plasma membrane. Although virus envelope 
fusion to the cell membrane is difficult to detect, the MV-induced cell-to-cell fusion which is 
mediated by MV H and F glycoproteins and CD46 is likely to involve similar molecular 
mechanisms (Naniche, et al., 1993).
Ligation of the CD46 receptor on PMNL by the CD46 antibody resulted in a decrease in the 
chemotaxis of PMNL. This decrease occurred in a dose-dependent manner; the highest reduction 
occurring in PMNL exposed to a higher dose of CD46 antibody. Also, apoptosis was found to 
be elevated in PMNL exposed to both the low and high concentration of this antibody. It is clear 
from these observations that occupation of the MV receptor, CD46, by a specific antibody, had 
a similar effect to that observed for the attachment of different MV strains to the receptor. 
Therefore, the mechanism(s) involved in the suppression of PMNL functions and induction of 
apoptosis appear to involve the binding of MV to its cellular receptor on PMNL. The significance 
of CD46 downregulation on PMNL following MV infection could be that the PMNL would 
become vulnerable to complement lysis, as the CD46 receptor would no longer be able to fulfill 
its main function of protecting the cell from complement-mediated destruction. The end result 
would be a reduction in both the number of circulating PMNL and in their functional capacity.
Taken together, these results show that MV has the ability to cause immune suppression in the 
host by directly incapacitating a number of PMNL functions and possibly reducing their numbers 
in the circulation through accelerated cell death (apoptosis). This most likely occurs at the stage 
of virus attachment. It is therefore likely that MV by binding to PMNL in vivo (in particular, the 
wild-type strain) plays an important role in compromising innate cellular immunity in the MV-
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infected host and so predispose the individual to secondary microbial infections.
An understanding of the mechanisms involved in MV-induced suppression of PMNL function, 
particularly at the stage of virus binding could lead to means of protecting PMNL from the direct 
effects of MV, and so protect the host from secondary bacterial or fungal infections. Further 
studies are required to elucidate the precise mechanism by which MV incapacitates PMNL, and 
to determine to what extent attenuated MV vaccines may impact on an already compromised 
innate cellular (PMNL) immune response particularly in those children bom to HIV-infected 
mothers that become infected within the first year of life.
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APPENDIX
Abbreviations
AIDS Acquired Immunodeficiency Syndrome
C C protein
CDC Centre for Disease Control
CDV Canine Distemper Virus
CMV Cytomegalovirus
CPE Cytopathic effects
CSF Cerebrospinal Fluid
CYT Cytoplasmic Tail
DHR Dihydrorhodamine
DTH Delayed type hypersensitivity
EBV Epstein Barr Virus
HI A Enzyme Immunoassay
ELISA Enzyme-linked Immunosorbent Assay
F Fusion protein
FCS Foetal Calf Serum
h hour
H Haemagghitinin
HI Heat Inactivated
HIV Human Immunodeficiency Virus
HLA Human Leukocyte Antigen
ICE Interleukin-1(3 Converting Enzyme
IF Immunofluorescence
IFN Interferon
Ig Immunoglobulin
DL-8 Interleukin-8
ISG Immune Serum Globulin
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M G Intravenous Immune Globulin
Kda Kilodalton
L Large protein
M Matrix protein
mAb monoclonal antibody
MHC Major Histocompatibility Complex
MV M easles Virus
N Nucleocapsid
NK Natural Killer cells
T im nanometre
OD Optical Density
P Phosphoprotein
PBMCs Pheripheral Blood Mononuclear Cells
PBS Phosphate Buffered Saline
PCR Polymerase Chain Reaction
PDV Phocine Distemper Virus
PMNL Polymorphonuclear leukocytes
R Rhodamme
RBC Red Blood Cells
ROI Reactive Oxygen Intermediates
rpm revolutions per minute
RT Reverse Transcriptase
SABTS South African Blood Transfusion Services
SCR Short Consensus Repeat
SEM Standard Error o f the Mean
SSPE Subacute Sclerosing Panencephalitis
STP Serine, Threonine, Proline
TNF Tumour Necrosis Factor
V Variable protein
WHO World Health Organisation
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